FIELD OF THE INVENTION
[0001] This invention relates to novel isoxazolines, their N-oxides and salts, processes
for their manufacture, their use in the control of ectoparasites, especially insects
and acari, on non-human animals, especially productive livestock and domestic animals,
and furthermore pesticidal compositions which contain one or more of these compounds.
BACKGROUND OF THE INVENTION
[0002] PCT Patent Publication
WO 2007/075459 discloses isoxazoline derivatives of Formula (A) as plant insecticides

wherein, inter alia, each of A
1, A
2 and B
1-B
3 are C(R
3), A
3 is N, R
1 is haloalkyl and Q is a heterocyclic radical.
[0003] The compounds are mainly used in the control of invertebrate pests in agronomic environments.
Many products are commercially available for these purposes, but the need continues
for new compounds that are more effective, less costly, less toxic, environmentally
safer or have different modes of action. It now has been surprisingly found that novel
derivatives with a modified heterocyclic side chain have superior properties in the
control of pests.
SUMMARY OF THE INVENTION
[0004] This present invention is directed to a compound of formula

including all geometric and stereoisomers, N-oxides, and salts thereof, and compositions
containing them and their use for controlling parasites, wherein
X, is S(O)
m, O or NR
5' and X
1 and X
2 are each independently of the other CR
3' or N,
n is an integer from 0 to 4; m is an integer from 0 to 2;
B
1, B
2 and B
3 are each independently selected from the group consisting of CR
2' and N;
each R
2' is independently of the other H or R
2;
each R
3' is independently of the other H or R
3;
R
1 is C
1-C
6-alkyl, C
2-C
6-alkenyl, C
2-C
6-alkynyl, C
3-C
6-cycloalkyl, C
4-C
7-alkylcycloalkyl or C
4-C
7-cycloalkylalkyl, each unsubstituted or substituted with one or more substituents
independently selected from R
4;
R
4 is halogen, C
1-C
6-alkyl, C
1-C
6-alkoxy, C
1-C
6-alkylthio, C
1-C
6-alkylsulfinyl, C
1-C
6-alkylsulfonyl, cyano or nitro;
each R
2 is independently halogen, C
1-C
6-alkyl, C
1-C
6-haloalkyl, C
1-C
6-alkoxy, C
1-C
6-haloalkoxy, C
1-C
6-alkylthio, C
1-C
6-haloalkylthio, C
1-C
6-alkylsulfinyl, C
1-C
6-haloalkylsulfinyl, C
1-C
6-alkylsulfonyl, C
1-C
6-haloalkylsulfonyl, N-mono- or N,N-di-C
1-C
6-alkylamino, C
1-C
6 alkoxycarbonyl, cyano (-CN) or nitro (-NO
2);
each R
3 is independently H, halogen, C
1-C
6-alkyl, C
1-C
6-haloalkyl, C
3-C
6-cycloalkyl, C
3-C
6-halocycloalkyl, C
1-C
6-alkoxy, C
1-C
6-haloalkoxy, C
1-C
6-alkylthio, C
1-C
6-haloalkylthio, C
1-C
6-alkyl-sulfinyl, C
1-C
6-haloalkylsulfinyl, C
1-C
6-alkylsulfonyl, C
1-C
6-haloalkylsulfonyl, amino, N-mono- or N,N-di-C
1-C
6-alkylamino, C
1-C
6-alkoxycarbonyl, cyano, nitro or unsubstituted or halogen-, C
1-C
6-alkyl-, C
1-C
6-haloalkyl-, C
1-C
6-alkoxy-, C
1-C
6-haloalkoxy-, amino-, cyano- or nitro-substituted phenyl, pyridyl or pyrimidyl;
Z is halogen, a radical Q or a group -C(W)-NR
5R
6;
Q is a 5- or 6-membered heterocyclic ring or a C
6-C
10-carbocyclic ring system or a 8-, 9- or 10-membered fused hetero-bicyclic ring system,
each of them being unsubstituted or substituted with one or more substituents independently
selected from halogen, C
1-C
6-alkyl, C
1-C
6-haloalkyl, C
3-C
6-cycloalkyl, C
3-C
6-halocycloalkyl, C
1-C
6-alkoxy, C
1-C
6-haloalkoxy, C
1-C
6-alkylthio, C
1-C
6-haloalkylthio, C
1-C
6-alkylsulfinyl, C
1-C
6-haloalkylsulfinyl, C
1-C
6-alkylsulfonyl, C
1-C
6-haloalkylsulfonyl, cyano, nitro, amino, N-mono- or N,N-di-C
1-C
4-alkylamino, C
1-C
6-alkoxycarbonyl, sulfonamido, N-mono- or N,N, di-C
1-C
4-alkylsulfonamido, C
1-C
6-alkylcarbonylamino, N-mono- or N,N-di-C
1-C
6-alkylaminocarbonyl, C
2-C
6-alkanoyl, a group -(alk)-C(W')NR
5 "R
7, phenyl, benzyl, benzoyl, phenoxy, pyridyl, pyridyl-(alk)-, pyrimidyl and pyrimidyl-(alk)-,
wherein the phenyl, benzyl, benzoyl, phenoxy, pyridyl and pyrimidyl are each unsubstituted
or substituted by halogen, C
1-C
6-alkyl, C
1-C
6-haloalkyl, C
1-C
6-alkoxy, C
1-C
6-haloalkoxy, cyano, nitro or amino;
(alk) is straight-chain or branched C
1-C
6-alkylene,
W and W' are each independently of the other O or S,
R
5, R
5' and R
5" are each independently of the other H, C
1-C
6-alkyl C
2-C
6-alkenyl, C
2-C
6-alkynyl, C
3-C
6-cycloalkyl, C
4-C
7-alkylcycloalkyl, C
4-C
7-cycloalkylalkyl, C
1-C
6-alkylcarbonyl or C
1-C
6-alkoxycarbonyl;
R
6 is H; Q', wherein Q' has independently the meaning of Q; or is C
1-C
6-alkyl, C
2-C
6-alkenyl, C
2-C
6-alkynyl, C
3-C
6-cycloalkyl, C
4-C
7-alkylcycloalkyl or C
4-C
7-cycloalkylalkyl, each unsubstituted or substituted by halogen, C
1-C
6-alkoxy, C
1-C
6-alkylthio, C
1-C
6alkylsulfinyl, C
1-C
6-alkylsulfonyl, cyano, nitro, amino, N-mono- or N,N-di-C
1-C
6-alkylamino, C
3-C
6-cycloalkylamino, C
1-C
6-alkoxycarbonyl, C
2-C
6-alkanoyl, C
1-C
6-alkylcarbonylamino, aminocarbonyl, N-mono- or N,N-di-C
1C
6-alkylaminocarbonyl, a group-C(W')NR
5R
7 or a radical Q", wherein Q" independently has the meaning of Q; or
R
5 and R
6 together with the N-atom to which they are attached, form a 3- to 7-membered ring
which optionally contains a further heteroatom selected from the group consisting
of N, S and O, and which ring is further unsubstituted or substituted by C
1-C
2-alkyl, C
1-C
2-alkyl, C
1-C
2-alkoxy, halogen, cyano, nitro; and
R
7 is C
1-C
6-alkyl, C
2-C
6-alkenyl, C
2-C
6-alkynyl, C
3-C
6-cycloalkyl, C
4-C
7-alkylcycloalkyl or C
4-C
7-cycloalkylalkyl, which may each be unsubstituted or substituted by halogen C
1-C
6-alkoxy, C
1-C
6-alkylthio, C
1-C
6-alkylsulfinyl, C
1-C
6-alkylsulfonyl, cyano, nitro, amino, N-mono- or N,N-di-C
1-C
6-alkylamino, pyridyl, pyrimidyl or thiazolyl, or by pyridyl, pyrimidyl or thiazolyl
being mono- or disubstiltuted by halogen, cyano, C
1-C
2-alkyl or C
1-C
2-haloalkyl.
[0005] According to a preferred embodiment of the invention, there is provided a compound
of formula (I) above, wherein
X is S(O)
m, O or NR
5' and X
1 and X
2 are each independently of the other CR
3' or N,
n is an integer from 0 to 4; m is an integer from 0 to 2;
B
1, B
2 and B
3 are each independently selected from the group consisting of CR
2' and N;
each R
2' is independently of the other H or R
2;
each R
3' is independently of the other H or R
3;
R
1 is C
1-C
6-alkyl, C
2-C
6-alkenyl, C
2-C
6-alkynyl, C
3-C
6-cycloalkyl, C
4-C
7-alkylcycloalkyl or C
4-C
7-cycloalkylalkyl, each unsubstituted or substituted with one or more substituents
independently selected from R
4;
R
4 is halogen, C
1-C
6-alkyl, C
1-C
6-alkoxy, C
1-C
6-alkylthio, C
1-C
6-alkylsulfinyl, C
1-C
6-alkylsulfonyl, cyano or nitro;
each R
2 is independently halogen, C
1-C
6-alkyl, C
1-C
6-haloalkyl, C
1-C
6-alkoxy, C
1-C
6-haloalkoxy, C
1-C
6alkylthio, C
1-C
6-haloalkylthio, C
1-C
6-alkylsulfinyl, C
1-C
6-haloalkylsulfinyl, C
1-C
6-alkylsulfonyl, C
1-C
6-haloalkylsulfonyl, N-mono- or N,N-di-C
1-C
6-alkylamino, C
2-C
6 alkoxycarbonyl, cyano (-CN) or nitro (-NO
2);
each R
3 is independently H, halogen, C
1-C
6-alkyl, C
1-C
6haloalkyl, C
3-C
6-cycloalkyl, C
3-C
6-halocycloalkyl, C
1-C
6-alkoxy, C
1-C
6-haloalkoxy, C
1-C
6-alkylthio, C
1-C
6-haloalkylthio, C
1-C
6 alkyl-sulfinyl, C
1-C
6-haloalkylsulfinyl, C
1-C
6-alkylsulfonyl, C
1-C
6-haloalkylsulfonyl, amino, N-mono- or N,N-di-C
1-C
6-alkylamino, C
2-C
6-alkoxycarbonyl, cyano or nitro;
Z is halogen, a radical Q or a group -C(W)-NR
5R
6;
Q is a 5- or 6-membered heterocyclic ring, or a C
6-C
10-carbocyclic ring system or a 8-, 9- or 10-membered fused hetero-bicyclic ring system,
each of them being unsubstituted or substituted with one or more substituents independently
selected from halogen, C
1-C
6-alkyl, C
1-C
6-haloalkyl, C
3-C
6-cycloalkyl, C
3-C
6-halocycloalkyl, C
1-C
6-alkoxy, C
1-C
6-haloalkoxy, C
1-C
6-alkylthio, C
1-C
6-haloalkylthio, C
1-C
6-alkylsulfinyl, C
1-C
6haloalkylsulfinyl, C
1-C
6-alkylsulfonyl, C
1-C
6-haloalkylsulfonyl, cyano, nitro, amino, N-mono- or N,N-di-C
1-C
4-alkylamino, C
1-C
6-alkoxycarbonyl, sulfonamido, N-mono- or N,N, di-C
1-C
4-alkylsulfonamido, C
1-C
6-alkylcarbonylamino, N-mono- or N,N-di-C
1-C
6-alkylaminocarbonyl, C
2-C
6-alkanoyl and unsubstituted or halogen-, C
1-C
6-alkyl-, C
1-C
6-haloalkyl-, C
1-C
6-alkoxy-, C
1-C
6-haloalkoxy-, Cyano, nitro, substituted phenyl, benzyl, benzoyl or phenoxy;
W is O or S,
R
5 and R
5' are each independently of the other H, C
1-C
6-alkyl, C
2-C
6-alkenyl, C
2-C
6-alkynyl, C
3-C
6-cycloalkyl, C
4-C
7-alkylcycloalkyl, C
4-C
7-cycloalkylalkyl, C
2-C
6-alkylcarbonyl or C
2-C
6-alkoxycarbonyl; and
R
6 is H; Q', wherein Q' has independently the meaning of Q; or is C
1-C
6-alkyl, C
2-C
6-alkenyl, C
2-C
6-alkynyl, C
3-C
6-cycloalkyl, C
4-C
7-alkylcycloalkyl or C
4-C
7-cycloalkylalkyl, each unsubstituted or substituted by halogen C
1-C
6-alkoxy, C
1-C
6-alkylthio, C
1-C
6-alkylsulfinyl, C
1-C
6-alkylsulfonyl, cyano, nitro, amino, N-mono- or N,N-di-C
1-C
6-alkylamino, C
3-C
6-cycloalkylamino, C
2-C
6-alkoxycarbonyl, C
2-C
6-alkanoyl, C
2-C
6-alkylcarbonylamino, aminocarbonyl, N-mono- or N,N-di-C
1C
6-alkylaminocarbonyl or a radical Q", wherein Q" independently has the meaning of Q;
or
R
5 and R
6 together with the N-atom to which they are attached, form a 3- to 7-membered ring
which optionally contains a further heteroatom selected from the group consisting
of N, S and O, and which ring is further unsubstituted or substituted by C
1-C
2-alkyl, C
1-C
2-alkyl, C
1-C
2-alkoxy, halogen, cyano or nitro.
[0006] This invention also provides a composition comprising a compound of formula (I),
an N-oxide or a salt thereof, and at least one additional component selected from
the group consisting of a surfactant, a solid diluent and a liquid diluent.
[0007] In one embodiment, this invention also provides a composition for controlling parasites,
in particular ectoparasites, comprising a biologically effective amount of a compound
of formula (I), an N-oxide or a salt thereof, and at least one additional component
selected from the group consisting of a surfactant, a solid diluent and a liquid diluent,
said composition optionally further comprising a biologically effective amount of
at least one additional biologically active compound or agent.
[0008] This invention further provides the composition described above in the form of a
bait composition wherein the solid diluent and/or the liquid diluent comprises one
or more food materials, said composition optionally comprising an attractant and/or
a humectant.
[0009] This invention further provides a trap device for controlling parasites, in particular
ectoparasites, comprising said bait composition and a housing adapted to receive said
bait composition, wherein the housing has at least one opening sized to permit the
parasites to pass through the opening, so the invertebrate pest can gain access to
said bait composition from a location outside the housing, and wherein the housing
is further adapted to be placed in or near a locus of potential or known activity
for the parasites pest.
[0010] This invention also provides a method for controlling parasites comprising contacting
the parasites or their environment with a biologically effective amount of a compound
of formula (I), an N-oxide or a salt thereof, (e.g., as a composition described herein).
This invention also relates to such method wherein the parasites or their environment
are contacted with a composition comprising a biologically effective amount of a compound
of formula (I), an N-oxide or a salt thereof, and at least one additional component
selected from the group consisting of a surfactant, a solid diluent and a liquid diluent,
said composition optionally further comprising a biologically effective amount of
at least one additional biologically active compound or agent.
[0011] This invention also provides a composition for protecting an animal, from an parasitic
pest comprising a parasiticidally effective amount of a compound of formula (I) an
N-oxide or a salt thereof, and at least one carrier. The present invention further
provides the composition described above in a form for oral administration. This invention
also provides a method for protecting an animal from a parasitic pest comprising administering
to the animal a parasiticidally effective amount of a compound of formula (I), an
N-oxide or a salt thereof.
DETAILS OF THE INVENTION
[0012] In the above recitations, the term "alkyl", used either alone or in compound words
such as "alkylthio" or "haloalkyl" includes straight-chain or branched alkyl, such
as, methyl, ethyl, n-propyl, i-propyl, or the different butyl, pentyl or hexyl isomers.
[0013] The radical (alk) denotes, for example, straight-chain or branched C
1-C
6-alkylene, for example ethylene, 1,1- or 1,2-ethylene or straight-chain or branched
propylene, butylene, pentylene or hexylene. (alk) is preferably straight-chain or
branched C
1-C
4-alkylene, more preferably C
1-C
2-alkylene, most preferably methylene, or 1,2-ethylene and in particular methylene.
[0014] "Alkenyl" includes straight-chain or branched alkenes such as ethenyl, 1-propenyl,
2-propenyl, and the different butenyl, pentenyl and hexenyl isomers. "Alkenyl" also
includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl.
[0015] "Alkynyl" includes straight-chain or branched alkynes such as ethynyl, 1-propynyl,
2-propynyl and the different butynyl, pentynyl and hexynyl isomers. "Alkynyl" can
also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl.
[0016] "Alkoxy" includes, for example, methoxy, ethoxy, n-propyloxy, isopropyloxy and the
different butoxy, pentoxy and hexyloxy isomers. "Alkylthio" includes branched or straight-chain
alkylthio moieties such as methylthio, ethylthio, and the different propylthio, butylthio,
pentylthio and hexylthio isomers.
[0017] "Alkylsulfinyl" includes both enantiomers of an alkylsulfinyl group. Examples of
"alkylsulfinyl" include CH
3S(O)-, CH
3CH
2S(O)-, CH
3CH
2CH
2(O)-, (CH
3)
2CHS(O)- and the different butylsulfinyl, pentylsulfinyl and hexylsulfinyl isomers.
[0018] Examples of "alkylsulfonyl" include CH
3S(O)
2-, CH
3CH
2S(O)
2-, CH
3CH
2CH
2S(O)
2-, (CH
3)
2CHS(O)
2-, and the different butylsulfonyl, pentylsulfonyl and hexylsulfonyl isomers.
[0019] "N-alkylamino", "N,N-di-alkyamino", and the like, are defined analogously to the
above examples.
[0020] "Cycloalkyl" includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
The term "alkylcycloalkyl" denotes alkyl substitution on a cycloalkyl moiety and includes,
for example, ethylcyclopropyl, i-propylcyclobutyl, 3-methylcyclopentyl and 4-methylcyclohexyl.
The term "cycloalkylalkyl" denotes cycloalkyl substitution on an alkyl moiety. Examples
of "cycloalkylalkyl" include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl
moieties bonded to straight-chain or branched alkyl groups,
[0021] The term "halogen", either alone or in compound words such as "haloalkyl", includes
fluorine, chlorine, bromine or iodine. Further, when used in compound words such as
"haloalkyl", said alkyl may be partially or fully substituted with halogen atoms which
may be the same or different. Examples of "haloalkyl" include F
3C-, ClCH
2, CF
3CH
2 and CF
3CCl
2. The terms "halocycloalkyl", "haloalkoxy", "haloalkylthio", and the like, are defined
analogously to the term "haloalkyl". Examples of "haloalkoxy" include CF
3O-, CCl
3CH
2O-, HCF
2CH
2CH
2O- and CF
3CH
2O-. Examples of "haloalkylthio" include CCl
3S-, CF
3S-, CCl
3CH
2S- and ClCH
2CH
2CH
2S-. Examples of "haloalkylsulfinyl" include CF
3S(O)-, CCl
3S(O)-, CF
3CH
2(O)- and CF
3CF
2S(O)-. Examples of "haloalkylsulfonyl" include CF
3S(O)
2-, CCl
3S(O)
2-, CF
3CH
2S(O)
2- and CF
3CF
2S(O)
2-.
[0022] "Alkylcarbonyl" denotes a straight-chain or branched alkyl moieties bonded to a C(=O)
moiety. Examples of "alkylcarbonyl" include CH
3C(=O)-, CH
3CH
2CH
2C(=O)- and (CH
3)
2CHC(=O)-. Examples of "alkoxycarbonyl" include CH
3OC(=O)-, CH
3CH
2OC(=O), CH
3CH
2CH
2OC(=O)-, (CH
3)
2CHOC(=O)- and the different butoxy- or pentoxycarbonyl isomers, for example tert.-butoxycarbonyl
(Boc).
[0023] The total number of carbon atoms in a substituent group is indicated by the "C
i-C
j" prefix where i and j are integers. For example, C
1-C
4 alkylsulfonyl designates methylsulfonyl through butylsulfonyl. C
2-alkoxyalkyl designates CH
3OCH
2; C
3-alkoxyalkyl designates, for example, CH
3CH(OCH
3), CH
3OCH
2CH
2 or CH
3CH
2OCH
2; and C
4-alkoxyalkyl designates the various isomers of an alkyl group substituted with an
alkoxy group containing a total of four carbon atoms, examples including CH
3CH
2CH
2OCH
2 and CH
3CH
2OCH
2CH
2-.
[0024] When a compound is substituted with a substituent bearing a subscript that indicates
the number of said substituents can exceed 1, said substituents (when they exceed
1) are independently selected from the group of defined substituents, e.g., (R
2)
n, n is 1 or 2. "Aromatic" indicates that each of the ring atoms is essentially in the
same plane and has ap-orbital perpendicular to the ring plane, and in which (4n +
2) π electrons, where n is a positive integer, are associated with the ring to comply
with Hückel's rule.
[0025] The terms "heterocyclic ring" or "heterocycle" denote a ring in which at least one
atom forming the ring backbone is not carbon, e.g., nitrogen, oxygen or sulfur. Typically
a heterocyclic ring contains no more than 4 nitrogens, no more than 2 oxygens and
no more than 2 sulfurs. Unless otherwise indicated, a heterocyclic ring can be a saturated,
partially unsaturated, or fully unsaturated ring. When a fully unsaturated heterocyclic
ring satisfies Hückel's rule, then said ring is also called a "heteroaromatic ring",
"aromatic heterocyclic ring". Unless otherwise indicated, heterocyclic rings and ring
systems can be attached through any available carbon or nitrogen by replacement of
a hydrogen on said carbon or nitrogen.
[0026] When Q is a 5- or 6-membered nitrogen-containing heterocyclic ring, it may be attached
to the remainder of formula (I) though any available carbon or nitrogen ring atom,
unless otherwise described.
[0027] Each R
2 is independently of the other preferably halogen, C
1-C
6-haloalkyl, C
1-C
6 haloalkoxy or cyano, more preferably halogen, CF
3, OCF
3 or cyano, and in particular halogen.
[0028] The variable n is meant to summarize all radicals R
2 in the 6-membered ring. n is preferably an integer from 0 to 4, more preferably from
1 to 3, and in particular 2 or 3.
[0029] B
1, B
2 and B
3 are each independently of the other preferred the group CR
2', wherein R
2' is H or R
2, and for R
2 the above-given meanings and preferences apply. R
2' is most preferably H or halogen.
[0030] R
1 is preferably C
1-C
6-alkyl optionally substituted with one or more substituents independently selected
from R
4, more preferably C
1-C
3-alkyl optionally substituted with halogen, even more preferably halo-C
1-C
3-alkyl, specially preferably C
1-C
2-alkyl substituted with F, and in particular CF
3.
[0031] R
4 is preferably halogen, C
1-C
2-alkyl, C
1-C
2-alkoxy, cyano or nitro, more preferably halogen, cyano or nitro, and in particular
halogen.
[0032] Each R
3 is independently of the other preferably halogen, C
1-C
4-alkyl, C
1-C
4-haloalkyl, C
3-C
6-cycloalkyl, C
1-C
4-alkoxy, C
1-C
4-haloalkoxy, N-mono- or N,N-di-C
1-C
6-alkylamino, cyano or nitro, more preferably halogen, C
1-C
2-alkyl, C
1-C
2-haloalkyl, cyclopropyl, C
1-C
2-alkoxy, cyano or nitro, even more preferably halogen, C
1-C
2alkyl, C
1-C
2-alkoxy, cyano or nitro, and in particular C
1-C
2-alkyl.
[0033] According to a further preferred embodiment of the invention, R
3 is phenyl, pyridyl or pyrimidyl, which is unsubstituted or substituted by halogen,
C
1-C
6-alkyl, C
1-C
6-haloalkyl, C
1-C
6-alkoxy, C
1-C
6-haloalkoxy, amino, cyano or nitro; preferably phenyl, pyridyl or pyrimidyl which
is unsubstituted or substituted by fluorine, chlorine, methyl, trifluoromethyl, methoxy,
trifluoromethoxy, amino, cyano or nitro; and in particular phenyl which is unsubstituted
or substituted by chlorine, fluorine, methyl or trifluoromethyl.
[0034] If X
1 or X
2 denote a group CR
3', R
3' is H or R
3, wherein for R
3 the above-given meanings and preferences apply. R
3' is preferably H, C
1-C
2-alkyl, halogen or cyano, most preferably H or C
1-C
2alkyl.
[0035] X is preferably S(O)
m, O or NR
5' and X
1 and X
2 are each independently CR
3' or N. More preferably, X is S(O)
m, O or NR
5', one of X
1 and X
2 is CR
3' and the other one is N or independently another CR
3'. Even more preferably, X is S(O)
m, one of X
1 and X
2 is CR
3' and the other one is N or independently another CR
3'. m is, for example 0, 1 or 2, in particular 0.
[0036] According to a particularly preferred embodiment of the invention X is S(O)
m, m is 0, 1 or 2, one of X
1 and X
2 is CR
3' and the other one is N or independently another CR
3', and R
3' is H, methyl, halogen, cyano or phenyl.
[0037] According to one preferred embodiment of the invention, Q is a C
6-C
10-carbocyclic ring system, for example phenyl, naphthyl, tetrahydronaphthyl, indanyl,
indenyl, hydrindanyl or octahydro-pentalen, in particular phenyl, which is each unsubstituted
or substituted by one or more same or different substituents selected from the group
of substituents as defined before for Q, Q is preferably phenyl which is substituted
by 1 to 4, preferably 1 to 3 and in particular 1 or 2 same or different substituents
selected from the group consisting of halogen, C
1-C
4-alkyl, C
1-C
4-haloalkyl, C
1-C
4-alkoxy, C
1-C
4-haloalkoxy, C
1-C
4-alkylthio, C
1-C
4-haloalkylthio, C
1-C
4-alkylsulfinyl, C
1-C
4-haloalkylsulfinyl, C
1-C
4-alkylsulfonyl, C
1-C
4-haloalkylsulfonyl, cyano, nitro, C
1-C
4-alkoxycarbonyl, sulfonamido, C
2-C
3-alkanoyl and unsubstituted or halogen-, C
1-C
4-alkyl-, C
1-C
4-haloalkyl-, C
1-C
4-alkoxy-, C
1-C
4-haloalkoxy-, cyano- or nitro-substituted phenyl, benzyl, benzoyl and phenoxy. Q is
more preferably phenyl, which is substituted by 1 to 3, in particular 1 or 2, same
or different substituents selected from the group consisting of halogen, C
1-C
2-alkyl, C
1-C
2-haloalkyl, C
1-C
2-alkoxy, C
1-C
2-haloalkoxy, C
1-C
2-haloalkylthio, cyano, nitro, and unsubstituted or halogen-, C
1-C
2-alkyl-, C
1-C
2-haloalkyl-, C
1-C
2-alkoxy-, C
1-C
2-haloalkoxy-, cyano- or nitro-substituted phenyl and phenoxy.
[0038] According to a further preferred embodiment of the invention, Q is phenyl which is
substituted by a group -(alk)-C(W')NR
5"R
7, wherein for (alk), W', R
5" and R
7 each the above and below given meanings and preferences apply.
[0039] According to another preferred embodiment of the invention, Q is a 5- or 6-membered
heterocyclic ring, which may be saturated or preferably unsaturated, and which is
unsubstituted or substituted with one or more substituents selected from the group
of substituents as defined before for Q.
[0040] Preferred substituents of the heterocyclic ring Q are, for example, C
1-C
4-alkyl, C
1-C
4-haloalkyl, C
1-C
4-alkoxy, C
1-C
4-haloalkoxy, C
1-C
4-alkylthio, C
1-C
4-haloalkylthio, C
1-C
4-alkylsulfinyl, C
1-C
4-haloalkylsulfinyl, C
1-C
4-alkylsulfonyl, C
1-C
4-haloalkylsulfonyl, cyano, nitro, C
1-C
4-alkoxycarbonyl, sulfonamido, N-mono- or N,N-di-C
1-C
4-alkylamino, C
2-C
3-alkanoyl and unsubstituted or halogen- or C
1-C
4-alkyl-substituted phenyl, benzyl, benzoyl and phenoxy. Even more preferred substituents
of the heterocyclic ring Q are selected from the group consisting of halogen, C
1-C
2-alkyl, C
1-C
2-haloalkyl, C
1-C
2-alkoxy, C
1-C
2-haloalkoxy, C
1-C
2-haloalkylthio, cyano, nitro, and C
1-C
4-alkoxycarbonyl, in particular C
1-C
2-alkyl, C
1-C
2-haloalkyl and C
1-C
4-alkoxycarbonyl.
[0041] A suitable heterocyclic ring is, for example, a 5- or 6-membered heteroaromatic ring
having from 1 to 4, preferably from 1 to 3 same or different heteroatoms selected
from the group consisting of N, O and S, which is further unsubstituted or substituted
by one or more substituents as defined before for Q including the preferences given
therefore. The heterocyclic radical Q is preferably substituted by 0 to 3, in particular
0, 1 or 2 substituents from the group as defined before for Q.
[0042] Examples of a 5- or 6-membered unsaturated aromatic heterocyclic ring optionally
substituted with from one or more substituents include the rings Q-1 through Q-60
illustrated in Exhibit 1 wherein R is any substituent as defined before for Q including
the preferences given, and r is an integer from 0 to 4, limited by the number of available
positions on each Q group. In addition, when the attachment point between (R)
r and the Q group is illustrated as floating, (R)
r can be attached to any available carbon atom or nitrogen atom of the Q group. As
Q-28,- Q-29, Q-35, Q-36, Q-37, Q-38, Q-39, Q-40, Q-41 and Q-42 have only one available
position, for these Q groups r is limited to the integers 0 or 1, and r being 0 means
that the Q group is unsubstituted and a hydrogen is present at the position indicated
by (R)
r.
Exhibit 1
[0044] A further group of suitable heterocyclic radicals comprises, for example, a 5- or
6-membered heteroaliphatic or partly unsaturated ring having from 1 to 4, preferably
from 1 to 3 same or different heteroatoms selected from the group consisting of N,
O and S, which is further unsubstituted or substituted by one or more substituents
as defined before for Q including the preferences given therefore.
[0045] Examples of heteroaliphatic or partly unsaturated rings include the radicals illustrated
in Exhibit 2 below, wherein R and r are as defined above including the preferences
given. Concerning the attachment point between (R)
r and the Q group, the same applies as mentioned before for radicals Q-1 to Q-60.
Exhibit 2
[0047] A preferred heterocyclic radical Q is of formula

wherein (R)
r is 0 to 3 same or different substituents selected from the group given for Q including
the preferences. Q is particularly preferred the unsubstituted radical Q-34, Q-43
or Q-47, wherein r is 0 in each case. According to a further preferred embodiment,
Q is an above-given radical Q-8, Q-44 or Q-47, wherein for R and r each the above
and below given meanings and preferences apply.
[0048] According to a further preferred embodiment of the invention, Q is a radical of formula

wherein r is 1, R is a radical -(alk)-C(W')-NR
5"R
7, (alk) is straight-chain or branched C
1-C
4-alkylene, W' is O or S, and R
5" and R
7 are each as defined above.
[0049] A particularly preferred radical Q is a radical of formula

wherein R is a radical -(alk)-C(O)-NHR
7, (alk) is methylene or 1,2-ethylene, in particular methylene, and R
7 is C
1-C
6-alkyl which is unsubstituted or substituted by halogen, cyano or pyridyl, or is C
2-C
4-alkynyl or C
3-C
4-cycloalkyl.
[0050] A suitable fused hetero-bicyclic ring system comprises, for example a 5- or 6-membered
heterocyclic ring having from 1 to 4, preferably from 1 to 3 same or different heteroatoms
selected from the group consisting of N, O and S, to which is attached an annulated
ring; in addition said fused bicyclic system is further unsubstituted or substituted
by one or more substituents as defined before for Q including the preferences given.
Those rings can be saturated ring or unsaturated rings.
[0051] Examples of fused hetero-bicyclic ring systems Q are illustrated in Exhibit 3 below.
Exhibit 3
[0053] Q is even more preferred the unsubstituted radical Q-105, Q106, Q-107, Q-108, Q-109,
Q-110 or Q-111, wherein r is 0 in each case. Particularly preferred fused bicyclic
structures Q are of formula

[0054] Q' independently has the meaning of Q including the above-given preferences. Q' is
most preferably a phenyl radical which is unsubstituted or substituted as defined
above for Q, or is a radical Q-1 to Q-60 as indicated in Exhibit 1, wherein for R
and r each the above given meanings and preferences apply. Q' is particularly preferred
phenyl which is unsubstituted or substituted by 1 to 3, in particular 1 or 2, same
or different substituents selected from the group consisting of halogen, C
1-C
2-alkyl, C
1-C
2-haloalkyl, C
1-C
2-alkoxy, C
1-C
2-haloalkoxy, C
1-C
2-haloalkylthio, cyano, nitro, and unsubstituted or halogen-, C
1-C
2-alkyl-, C
1-C
2-haloalkyl-, C
1-C
2-alkoxy-, C
1-C
2-haloalkoxy-, cyano- or nitro-substituted phenyl and phenoxy; or is a radical Q-5,
Q-6, Q-7, Q-14, Q-15, Q-16, Q-17, Q-24, Q-26, Q-30, Q-31, Q-32, Q-33, Q-34, Q-43,
Q-47, Q-48, Q-49, Q-50 and Q-54, wherein r is 0.
[0055] Q" independently has the meaning of Q including the above-given preferences. Q" is
most preferably a radical Q-34, Q-48, Q-49 or Q-50, wherein for R and r each the above
given meanings and preferences apply. Q" is particularly preferred the radical Q-34
or Q-48, wherein r is 0.
[0056] Z as halogen preferably denotes, Br, Cl or F, in particular Br.
[0057] If Z is a group -C(W)-NR
5R
6, W is preferably O.
[0058] R
5, R
5' and R
5" are each independently of the other preferably, H, C
1-C
6-alkyl, C
2-C
7-alkylcarbonyl or C
2-C
7-alkoxycarbonyl, more preferably, H, C
1-C
2-alkyl, C
2-C
4-alkylcarbonyl or C
2-C
4-alkoxycarbonyl, in particular H.
[0059] R
6 is preferably C
1-C
4-alkyl, C
2-C
4-alkenyl, C
2-C
4-alkynyl, C
3-C
6-cycloalkyl, C
4-C
7-alkylcycloalkyl or C
4-C
7-cycloalkylalkyl, each unsubstituted or substituted by halogen C
1-C
4-alkoxy, C
1-C
2-alkylthio, cyano, nitro, C
2-C
4-alkoxycarbonyl, C
2-C
4-alkanoyl, C
2-C
5-alkylcarbonylamino or a radical Q', wherein Q' independently has the meaning of Q
including the preferences given.
[0060] R
6 is more preferably C
1-C
4-alkyl which substituted by halogen C
1-C
4-alkoxy, C
1-C
2-alkylthio, cyano, nitro, C
2-C
4-alkoxycarbonyl, C
2-C
4-alkanoyl, C
2-C
5-alkylcarbonylamino or by a radical Q', wherein Q' independently has the meaning of
Q including the preferences given.
[0061] R
6 is even more preferably C
1-C
4-alkyl which is substituted by halogen, cyano, nitro or a radical Q', wherein Q' is
an above-given radical Q-34, Q-48, Q-49 or Q-50, wherein for R and r each the above
given meanings and preferences apply.
[0062] R
6 is particularly preferably C
1-C
2-alkyl which is substituted by halogen, especially by fluorine, or by the radical
Q-34 or Q-48, wherein r is in each case 0.
[0063] R
7 is preferably C
1-C
6-alkyl which is unsubstituted or substituted by halogen C
1-C
4-alkoxy, C
1-C
2-alkylthio, cyano, nitro, amino, N-mono- or N,N-di-C
1-C
4alkylamino, pyridyl, pyrimidyl thiazolyl, or pyridyl, pyrimidyl or thiazolyl which
is each mono- or disubstituted by halogen, cyano, C
1-C
2-alkyl or C
1-C
2-haloalkyl, or R
7 is C
2-C
4-alkenyl, C
2-C
4-alkynyl or C
3-C
6-cycloalkyl. R
7 is more preferably C
1-C
6-alkyl which is unsubstituted or substituted by halogen C
1-C
2-alkoxy, cyano, nitro, amino, N-mono- or N,N-di-C
1-C
2-alkylamino, pyridyl, pyrimidyl or thiazolyl, or R
7 is C
2-C
4-alkenyl, C
2-C
4-alkynyl or C
3-C
6-cycloalkyl. R
7 is in particular C
1-C
6-alkyl which is unsubstituted or substituted by halogen, cyano or pyridyl, or is C
2-C
4-alkynyl or C
3-C
4-cycloalkyl.
[0064] Z is preferably halogen; or a radical Q-5, Q-6, Q-7, Q-14, Q-15, Q-16, Q-17, Q-24,
Q-26, Q-30, Q-31, Q-32, Q-33, Q-34, Q-43, Q-47, Q-48, Q-49, Q-50, and Q-54, wherein
for R and r each the above given meanings and preferences apply; or is a group -C(O)-NR
5R
6, wherein R
5 is H, C
1-C
2-alkyl, C
2-C
4-alkylcarbonyl or C
2-C
4-alkoxycarbonyl and R
6 is C
1-C
4-alkyl which is substituted by halogen, cyano, nitro or a radical Q-34, Q-48, Q-49
or Q-50, wherein for R and r independently each the above given meanings and preferences
apply.
[0065] Z is most preferably halogen; or a radical Q-34, Q-43 or Q-47, wherein r is each
0; or is a group -C(O)-NR
5R
6, wherein R
5 is H and R
6 is C
1-C
4-alkyl which is substituted by halogen or a radical Q-34 or Q-48, wherein r is each
0.
[0066] According to a further preferred embodiment of the invention Z is a radical -C(W)-NR
5R
6, wherein W is O or S, for R
5 the above-given meanings and preferences apply, and R
6 is C
1-C
6-alkyl substituted by a radical -C(W')-NR
5"R
7, wherein for W', R
5" and R
7 the above-given meanings and preferences apply. Z is most preferably a radical -C(O)NR
5R
6, wherein R
5 is H, R
6 is -C
1-C
4-alkyl substituted by -C(O)NR
5"R
7, in particular methyl substituted by -C(O)NR
5"R
7, wherein R
5'' is in each case H, and R
7 is C
1-C
6-alkyl which is unsubstituted or substituted by halogen, cyano or pyridyl, or is C
2-C
4-alkynyl or C
3-C
4-cycloalkyl.
[0067] According to a preferred embodiment of the invention there is provided a compound
of formula

including all geometric and stereoisomers, N-oxides, and salts thereof, wherein for
R
1, R
2, X, X
1, X
2, Z and n each the above-given meanings and preferences apply.
[0068] In particular, n is an integer from 1 to 3, R
1 is halogen-substituted C
1-C
3-alkyl, each R
2 is independently selected from the group consisting of halogen, C
1-C
6-haloalkyl, C
1-C
6-haloalkoxy and cyano, X is S(O)
m, O or NR
5', m is an integer from 0 to 2, R
5' is H or C
1-C
2-alkyl, one of X
1 and X
2 is CR
3' and the other one is N or independently CR
3', R
3' is H or C
1-C
2-alkyl, and Z is halogen; or a radical Q-5, Q-6, Q-7, Q-14, Q-15, Q-16, Q-17, Q-24,
Q-26, Q-30, Q-31, Q-32, Q-33, Q-34, Q-43, Q-47, Q-48, Q-49, Q-50, and Q-54, wherein
for R and r each the above given meanings and preferences apply; or is a group -C(O)-NR
5R
6, wherein R
5 is H, C
1-C
2-alkyl, C
2-C
4-alkylcarbonyl or C
2-C
4-alkoxycarbonyl and R
6 is C
1-C
4-alkyl which is substituted by halogen, cyano, nitro or a radical Q-34, Q-48, Q-49
or Q-50, wherein for R and r independently each the above given meanings and preferences
apply.
[0069] A particularly preferred embodiment of the invention relates to a compound of formula
(Ia) above, wherein n is an integer from 1 to 3, R
1 is CF
3, each R
2 is independently selected from the group consisting of halogen, C
1-C
6-haloalkyl, C
1-C
6 haloalkoxy and cyano, X is S(O)
m, m is an integer from 0 to 2, in particular 0, one of X
1 and X
2 is CR
3' and the other one is N or independently CR
3', R
3' is H or C
1-C
2-alkyl, and Z is a radical Q-34, wherein r is 0; or is a group -C(O)-NR
5R
6, wherein R
5 is H and R
6 is C
1-C
4-alkyl which is substituted by halogen or a radical Q-34 or Q-48, wherein r is each
0.
[0070] A further particularly preferred embodiment of the invention relates to a compound
of formula (la) above, wherein n is an integer from 1 to 3, R
1 is CF
3, each R
2 is independently selected from the group consisting of halogen, C
1-C
6-haloalkyl, C
1-C
6 haloalkoxy and cyano, X is S(O)
m, m is an integer from 0 to 2, one of X
1 and X
2 is CR
3' and the other one is N or independently CR
3', R
3' is H or C
1-C
2-alkyl, and Z is a group -C(O)-NR
5R
6, wherein R
5 is H and R
6 is C
1-C
2-alkyl, in particular methyl, substituted in each case by a radical -C(O)-NR
5"R
7, wherein R
5" is H and R
7 is C
1-C
6-alkyl which is unsubstituted or substituted by halogen, cyano or pyridyl, or is C
2-C
4-alkynyl or C
3-C
4-cycloalkyl.
[0071] Compounds of this invention can exist as one or more stereoisomers. The various stereoisomers
include enantiomers, diastereomers, atropisomers and geometric isomers. One skilled
in the art will appreciate that one stereoisomer may be more active and/or may exhibit
beneficial effects when enriched relative to the other stereoisomer(s) or when separated
from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate,
enrich, and/or to selectively prepare said stereoisomers. The compounds of the invention
may be present as a mixture of stereoisomers, individual stereoisomers, or as an optically
active form.
One skilled in the art will appreciate that not all nitrogen containing heterocyclic
rings can form N-oxides since the nitrogen requires an available lone pair for oxidation
to the oxide; one skilled in the art will recognize those nitrogen containing heterocyclic
rings which can form N-oxides. One skilled in the art will also recognize that tertiary
amines can form N-oxides. Synthetic methods for the preparation of N-oxides of heterocyclic
rings and tertiary amines are very well known by one skilled in the art including
the oxidation of heterocyclic rings and tertiary amines with peroxy acids such as
peracetic and m-chloroperbenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides
such as t-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyl dioxirane
These methods for the preparation of N-oxides have been extensively described and
reviewed m the literature.
[0072] One skilled in the art recognizes that because of the environment and under physiological
conditions salts of chemical compounds are in equilibrium with their corresponding
nonsalt forms, salts share the biological utility of the nonsalt forms. Thus a wide
variety of salts of the compounds of formula (I) are useful for control of invertebrate
pests (i.e. are veterinarily or agriculturally suitable). The salts of the compounds
of formula (I) include acid-addition salts with inorganic or organic acids such as
hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric,
lactic, maleic, malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic
or valeric acids. When a compound of formula (I) contains an acidic moiety such as
a carboxylic acid or phenol, salts also include those formed with organic or inorganic
bases such as pyridine, triethylamine or ammonia, or amides, hydrides, hydroxides
or carbonates of sodium, potassium, lithium, calcium, magnesium or barium. Accordingly,
the present invention comprises compounds selected from formula (I), N-oxides and
veterinary acceptable and agriculturally suitable salts thereof.
[0073] The compounds of the present invention made be prepared, for example, in analogy
to the processes as outlined in
WO 2007/75459 on pages 29-31. Accordingly, the compounds of formula (I) or (Ia) may be prepared,
for example, by cycloaddition of a compound of formula

with a nitrile oxide derived from an oxime of formula

wherein B
1-B
3, R
1, R
2 X, X
1, X
2, and Z each have the above-given meaning.
[0074] The reaction typically proceeds through the intermediacy of an in situ generated
hydroxamyl chloride. In a typical procedure a chlorinating reagent such as sodium
hypochlorite, N-chlorosuccinimide, or chloramine-T is combined with the oxime in the
presence of the styrene. Depending on the conditions amine bases such as pyridine
or triethylamine may be necessary. The reaction can be run in a wide variety of solvents
including tetrahydrofuran, diethyl ether, methylene chloride, dioxane, and toluene
with optimum temperatures ranging from room temperature to the reflux temperature
of the solvent.
[0075] The compounds of formula (I) or (la) may also be prepared by a process in analogy
of
WO2009/025983, wherein a compound of formula (VI) is contacted with hydroxylamine and a base to
form an isoxazole of formula (I)

wherein B
1-B
3, R
1, R
2 X, X
1, X
2, Z and n each have the above-given meaning. The reaction may be performed as described
in
WO2009/025983 on pages 29-31. In addition, synthetic routes to prepare the intermediate of formula
(VI) are likewise disclosed in
WO2009/025983 on pages 31-34.
[0076] The compounds of formula (I) or (Ia), wherein Z is a 5-membered N-linked heterocyclic
ring can also be prepared by direct displacement of a leaving group of formula

wherein B
1-B
3, R
1, R
2 X, X
1 and X
2, each have the above-given meaning and Y is halogen, for example Br or F, tosylate,
triflate or nitro, with a compound of the formula
Z' - H (V),
wherein Z' is an azole heterocyclic ring, in the presence of a base. Typical azole
heterocyclic rings of formula (V) include optionally substituted pyrazoles, imidazoles,
triazoles and tetrazoles. Bromides can be displaced with the use of copper iodide
and a palladium catalyst, see for example
Kanemasa et al., European Journal of Organic Chemistry, 2004, 695-709. For direct fluorine displacement the reaction is typically run in a polar aprotic
solvent such as N,N-dimethylformamide or N,N-dimethylacetamide and in the presence
of an inorganic base such as sodium or potassium carbonate.
[0077] Another process for the preparation of compounds of the formula (I) or (Ia), wherein
Z is a group -C(W)- NR
5R
6, includes the aminocarbonylation of an arylbromide or iodide of the above formula
(IV), wherein Y is Br of I, with an amino compound HNR
5R
6 and CO. The reaction is typically carried out in the presence of a palladium catalyst
under CO atmosphere. Many catalysts are useful for this type of transformation; a
typical catalyst is tetrakis(triphenylphosphine)palladium(0). Solvents such as 1,2.dimethoxyethane,
N,N-dimethylacetamide or toluene are suitable. The method can be conducted over a
wide range of temperatures, for example from about 25°C to about 150°C, especially
from 60 to 110°C.
[0078] The compounds of formula (II) are known, for example, from
WO 2006/49459 or may be prepared in analogy to the methods disclosed therein.
[0079] The compounds of formula (III) may be prepared, for example, by first of all protecting
the aldehyde group of a compound of formula

wherein X, X
1 and X
2 are each as described above and Y is a leaving group as described above, for example,
by converting it to a cyclic acetal, then introducing a suitable radical Z replacing
Y by methods known from textbook of organic chemistry, afterwards deprotecting the
aldehyde and converting it to a hydroxyimino compound of formula III in a manner as
known from
WO 2007/75459.
[0080] The compounds of the formula (I) according to the invention are notable for their
broad activity spectrum and are valuable active ingredients for use in pest control.
They are particularly suitable in the control of ectoparasites and to a certain extent
also for controlling endoparasites on and in animals and in the hygiene field, whilst
being well tolerated by warm-blooded animals.
[0081] Animals in the context of the invention are understood to include warm-blooded animals
including farm animals, such as cattle, horses, pigs, sheep and goats, poultry such
as chickens, turkeys, guinea fowls and geese, fur-bearing animals such as mink, foxes,
chinchillas, rabbits and the like, as well as companion animals such as ferrets, guinea
pigs, rats, hamster, cats and dogs, and also humans.
[0082] In the context of the present invention, ectoparasites are understood to be in particular
insects, acari (mites and ticks), and crustaceans (sea lice). These include insects
of the following orders: Lepidoptera, Coleoptera, Homoptera, Hemiptera, Heteroptera,
Diptera. Dictyoptera, Thysanoptera, Orthoptera, Anoplura, Siphonaptera, Mallophaga,
Thysanura, Isoptera, Psocoptera and Hymenoptera. However, the ectoparasites which
may be mentioned in particular are those which trouble humans or animals and carry
pathogens, for example flies such as Musca domestica, Musca vetustissima, Musca autumnalis,
Fannia canicularis, Sarcophaga carnaria, Lucilia cuprina, Lucilia sericata, Hypoderma
bovis, Hypoderma lineatum, Chrysomyia chloropyga, Dermatobia hominis, Cochliomyia
hominivorax, Gasterophilus intestinalis, Oestrus ovis, biting flies such as Haematobia
irritans irritans, Haematobia irritans exigua, Stomoxys calcitrans, horse-flies (Tabanids)
with the subfamilies of Tabanidae such as Haematopota spp. (e.g. Haematopota pluvialis)
and Tabanus spp, (e.g.Tabanus nigrovittatus) and Chrysopsinae such as Chrysops spp.
(e.g. Chrysops caecutiens); Hippoboscids such as Melophagus ovinus (sheep ked); tsetse
flies, such as Glossinia spp.; other biting insects like midges, such as Ceratopogonidae
(biting midges), Simuliidae (Blackflies), Psychodidae (Sandflies); but also blood-sucking
insects, for example mosquitoes, such as Anopheles spp, Aedes spp and Culex spp, fleas,
such as Ctenocephalides felis and Ctenocephalides canis (cat and dog fleas), Xenopsylla
cheopis, Pulex irritans. Ceratophyllus gallinae, Dermatophilus penetrans, blood-sucking
lice (Anoplura) such as Linognathus spp, Haematopinus spp, Solenopotes spp, Pediculus
humanis; but also chewing lice (Mallophaga) such as Bovicola (Damalinia) ovis, Bovicola
(Damalinia) bovis and other Bovicola spp.. Ectoparasites also include members of the
order Acarina, such as mites (e.g. Chorioptes bovis, Cheyletiella spp., Dermanyssus
gallinae, Ortnithonyssus spp., Demodex canis, Sarcoptes scabiei, Psoroptes ovis and
Psorergates spp. and ticks. Known representatives of ticks are, for example, Boophilus,
Amblyomma, Anocentor, Dermacentor, Haemaphysalis, Hyalomma, Ixodes, Rhipicentor, Margaropus,
Rhipicephalus, Argas, Otobius and Ornithodoros and the like, which preferably infest
warm-blooded animals including farm animals, such as cattle, horses, pigs, sheep and
goats, poultry such as chickens, turkeys, guineafowls and geese, fur-bearing animals
such as mink, foxes, chinchillas, rabbits and the like, as well as companion animals
such as ferrets, guinea pigs, rats, hamster, cats and dogs, but also humans.
The compounds of the formula (I) according to the invention are also active against
all or individual development stages of animal pests showing normal sensitivity, as
well as those showing resistance to widely used parasiticides. This is especially
true for resistant insects and members of the order Acarina. The insecticidal, ovicidal
and/or acaricidal effect of the active substances of the invention can manifest itself
directly, i.e. killing the pests either immediately or after some time has elapsed,
for example when moulting occurs, or by destroying their eggs, or indirectly, e.g.
reducing the number of eggs laid and/or the hatching rate, good efficacy corresponding
to a pesticidal rate (mortality) of at least 50 to 60%. Compounds of the formula (I)
can also be used against hygiene pests, especially of the order Diptera of the families
Muscidae, Sarcophagidae, Anophilidae and Culicidae; the orders Orthoptera, Dictyoptera
(e.g. the family Blattidae (cockroaches), such as Blatella germanica, Blatta orientalis,
Periplaneta americana) and Hymenoptera (e.g. the families Formicidae (ants) and Vespidae
(wasps).
[0083] Surprisingly, the compounds of formula (I) are also effective against ectoparasites
of fishes, especially the sub-class of Copepoda (e.g. order of Siphonostomatoida (sea
lice), whilst being well tolerated by fish.
[0084] The compounds of formula (I) can also be used against hygiene pests, especially of
the order
Diptera of the families
Sarcophagidae, Anophilidae and
Culicidae; the orders
Orthoptera, Dictyoptera (e.g. the family
Blattidae) and
Hymenoptera (e.g. the family
Formicidae)
.
Compounds of the formula (I) also have sustainable efficacy on parasitic mites and
insects of plants. In the case of spider mites of the order
Acarina, they are effective against eggs, nymphs and adults of
Tetranychidae (Tetranychus spp. and
Panonychus spp.).
They have high activity against sucking insects of the order
Homoptera, especially against pests of the families
Aphididae, Delphacidae, Cicadellidae, Psyllidae, Loccidae, Diaspididae and
Eriophydidae (e.g. rust mite on citrus fruits); the orders
Hemiptera, Heteroptera and
Thysanoptera, and on the plant-eating insects of the orders
Lepidoptera, Coleoptera, Diptera and
Orthoptera
[0085] They are similarly suitable as a soil insecticide against pests in the soil.
The compounds of formula (I) are therefore effective against all stages of development
of sucking insects and eating insects on crops such as cereals, cotton, rice, maize,
soya, potatoes, vegetables, fruit, tobacco, hops, citrus, avocados and other crops.
The compounds of formula I are also effective against plant nematodes of the species
Meloidogyne, Heterodera, Pratylenchus, Ditylenchus, Radopholus, Rizoglyphus etc.
Certain compounds of the formula (I) seem to be also effective against certain species
of helminths.
[0086] Helminths are commercially important because they cause serious diseases in mammals
and poultry, e g. in sheep, pigs, goats, cattle, horses, donkeys, camels, dogs, cats,
rabbits, guinea-pigs, hamsters, chicken, turkeys, guinea fowls and other farmed birds,
as well as exotic birds. Typical nematodes are: Haemonchus, Trichostrongylus, Ostertagia,
Nematodirus, Cooperia, Ascaris, Bunostonum, Oesophagostonum, Charbertia, Trichuris,
Strongylus, Trichonema, Dictyocaulus, Capillaria, Heterakis, Toxocara, Ascaridia,
Oxyuris, Ancylostoma, Uncinaria, Toxascaris and Parascaris. The trematodes include,
in particular, the family of Fasciolideae, especially Fasciola hepatica.
The good pesticidal activity of the compounds of formula (I) according to the invention
corresponds to a mortality rate of at least 50-60% of the pests mentioned, more preferably
to a mortality rate over 90%, most preferably to 95-100%. The compounds of formula
(I) are preferably employed internally and externally in unmodified form or preferably
together with the adjuvants conventionally used in the art of formulation and may
therefore be processed in a known manner to give, for example, liquid formulations
(e.g spot-on, pour-on, spray-on, emulsions, suspensions, solutions, emulsifiable concentrates,
solution concentrates), semi-solid formulations (e g. creams, ointments, pastes, gels,
liposomal preparations) and solid preparations (e.g food additives tablets including
e. g. capsules, powders including soluble powders, granules, or embeddings of the
active ingredient in polymeric substances, like implants and microparticles). As with
the compositions, the methods of application are selected in accordance with the intended
objectives and the prevailing circumstances.
The formulation, i.e. preparations containing the active ingredient of formula (I),
or combinations of these active ingredients with other active ingredients, and optionally
a solid, semi-solid or liquid adjuvant, are produced in a manner known per se, for
example by intimately mixing, kneading or dispersing the active ingredients with compositions
of excipients, whereby the physiological compatibility of the formulation excipients
must be taken into consideration.
[0087] The solvents in question may be: alcohols (aliphatic and aromatic), such as benzylalcohol,
ethanol, propanol, isopropanol or butanol, fatty alcohols, such as oleyl alcohol and
glycols and their ethers and esters, such as glycerin, propylene glycol, dipropylene
glycol ether, ethylene glycol, ethylene glycol monomethyl or -ethyl ether and butyl
dioxytol, carbonates, such as propylene carbonate, ketones, such as cyclohexanone,
isophorone or diacetanol alcohol and polyethylene glycols, such as PEG 300. In addition,
the compositions may comprise strong polar solvents, such as N-methyl-2-pyrrolidone,
dimethyl sulfoxide or dimethylformamide, or water, fatty acid esters, such as ethyl
oleate or isopropylpalmitate, vegetable oils, such as rape, castor, coconut, or soybean
oil, synthetic mono-, di-, triglycerides like e.g. glyceryl monostearate and medium
chain triglycerides and also, if appropriate, silicone oils. The mentioned ingredients
may also serve as carrier for particulate application froms.
[0088] As ointment base resp. structure building ingredients the following excipients may
be used: Petroleum based substances, such as Vaseline or paraffines, bases made from
wool fat, like e.g. lanolin or lanolin alcohols, polyethylene glycols like e.g. macrogols
and lipid bases like e.g. phospholipids or triglycerids, such as hydrogenated vegetable
oils.
[0089] The use of emulsifiers, wetting agents and spreading agents may also be required,
in general, lecithins like soy lecithin, salts of fatty acids with alkaline earth
and alkali metals, alkyl sulfates like sodium cetylstearyl sulphate, cholates, fatty
alcohols like cetyl alcohol, sterols like cholestesterol, polyoxyethylene sorbitan
fatty acid esters like polysorbate 20, sorbitan fatty acid esters like sorbitan mono
laureate, fatty acid esters and fatty alcohol ethers of polyoxyethylene like poloxyl
oleyl ether, polyoxypropylene polyoxyethylene block copolymers as e.g. Pluronic™,
saccharose esters like saccharose distearate, polyglyceryl fatty acid esters like
polyglycerol oleate and fatty acid esters like e.g. ethyl oleate or isopropylmyristate.
[0090] The formulations may also include gelifying and stiffening agents, like e.g. polyacrylic
acid derivatives, cellulose ethers, polyvinyl alcohols, polyvinylpyrrolidons and fine
disperse silicium dioxide.
[0091] As polymeric agents with controlled release properties, may be applied derivatives
made by e.g. polylactic acid, polylactic coglycolic acid, poly orthoester, polyethylene
carbonate, poly anhydrids and starch and PVC based matrices.
[0092] The addition of penetration enhancers like ketones, sulfoxides, amides, fatty acid
esters and fatty alcohols may be necessary.
[0093] Also preservatives like sorbic acid, benzyl alcohol and parabenes, and antioxidants
as e.g. alpha tocopherol may be added.
[0094] The active ingredient or combinations of the active ingredient may also applied in
capsules, like hard gelatine capsules or soft capsules.
[0095] The binders for tablets and boli may be chemically modified polymeric natural substances
that are soluble in water or in alcohol, such as starch, cellulose or protein derivatives
(e.g. methyl cellulose, carboxymethyl cellulose, ethylhydroxyethyl cellulose, proteins
such as zein, gelatin and the like), as well as synthetic polymers, such as polyvinyl
alcohol, polyvinyl pyrrolidone etc. The tablets also contain fillers (e.g. starch,
microcrystalline cellulose, sugar, lactone etc.), lubricants (e.g. magnesium stearate),
glidants (e.g. colloidal silicon dioxide) and disintegrants (e.g. cellulose derivatives)
and acid resistant coatings, like e.g. acrylic acid esters.
[0096] The compounds of formula (I) according to the invention may be used alone or in combination
with other biocides. They may be combined with pesticides having the same sphere of
activity e.g. to increase activity, or with substances having another sphere of activity
e.g. to broaden the range of activity. It can also be sensible to add so-called repellents.
For example, in case of a compound of formula (I) having a particular efficacy as
adulticide, i.e. since it is effective in particular against the adult stage of the
target parasites, the addition of a pesticide which instead attack the juvenile stages
of the parasites may be very advantageous, or vice versa. In this way, the greatest
part of those parasites that produce great economic damage will be covered. Moreover,
this action will contribute substantially to avoiding the formation of resistance.
Many combinations may also lead to synergistic effects, i.e. the total amount of active
ingredient can be reduced, which is desirable from an ecological point of view. Preferred
groups of combination partners and especially preferred combination partners are named
in the following, whereby combinations may contain one or more of these partners in
addition to a compound of formula (I). Suitable partners in the mixture may be biocides,
e.g. the insecticides and acaricides with a varying mechanism of activity, which are
named in the following and have been known to the person skilled in the art for a
long time, e.g. chitin synthesis inhibitors, growth regulators; active ingredients
which act as juvenile hormones; active ingredients which act as adulticides; broad-band
insecticides, broad-band acaricides and nematicides; and also the well known anthelminthics
and insect- and/or acarid-deterring substances, said repellents or detachers. Non-limitative
examples of suitable insecticides and acaricides are mentioned in
WO 2009/071500, compounds Nos. 1-284 on pages 18-21. Non-limitative examples of suitable anthelminthics
are mentioned in
WO 2009/071500, compounds (A1) - (A31) on page 21. Non-limitative examples of suitable repellents
and detachers are mentioned in
WO 2009/071500, compounds (R1)-(R3) on page 21 and 22. Non-limitative examples of suitable synergists
are mentioned in
WO 2009/071500, compounds (S1) -(S3) on page 22. The said partners in the mixture are best known
to specialists in this field. Most are described in various editions of the
Pesticide Manual, The British Crop Protection Council, London, and others in the various editions of
The Merck Index, Merck & Co., Inc., Rahway, New Jersey, USA or in patent literature.
[0097] As a consequence of the above details, a further aspect of the present invention
relates to a combination preparation for the control of parasites on warm-blooded
animals, characterised in that it contains, in addition to a compound of formula (I),
at least one further active ingredient having the same or different sphere of activity
and at least one physiologically acceptable carrier. The present invention is not
restricted to two-fold combinations.
[0098] As a rule, the insecticidal and acaricidal compositions according to the invention
contain 0.1 to 99 % by weight, especially 0.1 to 95 % by weight of one or more active
ingredients of formula (I), 99.9 to 1 % by weight, especially 99.8 to 5 % by weight
of a solid or liquid admixture, including 0 to 25 % by weight, especially 0.1 to 25
% by weight of a surfactant. Application of the compositions according to the invention
to the animals to be treated may take place topically, perorally, parenterally or
subcutaneously, the composition being present, for example, in the form of solutions,
emulsions, suspensions, (drenches), powders, tablets, boli, capsules, chewable treats,
collars, eartags and pour-on formulations. Preferred topical formulations are understood
to refer to a ready-to-use solution in form of a spot-on, pour-on or spray-on formulation
often consisting of a dispersion or suspoemulsion or a combination of active ingredient
and spreading auxiliaries. The expression spot-on or pour-on method is understood
to refer to a ready-to-use concentrate intended to be applied topically and locally
on the animal. This sort of formulation is intended to be applied directly to a relatively
small area of the animal, preferably on the animal's back and breech or at one or
several points along the line of the back and breech. It is applied as a low volume
of about 0.05 to 1 ml per kg, preferably about 0.1 ml per kg, with a total volume
from 0.1 to 100 ml per animal, preferably limited to a maximum of about 50 ml. However,
it goes without saying that the total volume has to be adapted to the animal that
is in need of the treatment and will clearly be different, for example, in young cats
and in cattle. These pour-on and spot-on formulations are designed to spread all around
the animal giving protection or treatment to almost any part of the animal. Even so
the administration is carried out by applying a swab or spray of the pour-on or spot-on
formulation to a relatively small area of the coat, one observes that from the active
substance is dispersed almost automatically over wide areas of the fur owing to the
spreading nature of the components in the formulation and assisted by the animal's
movements.
[0099] Pour-on or spot-on formulations suitably contain carriers, which promote rapid dispersement
over the skin surface or in the coat of the host animal, and are generally regarded
as spreading oils. Suitable carriers are e.g. oily solutions; alcoholic and isopropanolic
solutions such as solutions of 2-octyldodecanol or oleyl alcohol; solutions in esters
of monocarboxylic acids, such as isopropyl myristate, isopropyl palmitate, lauric
acid oxalate, oleic acid oleyl ester, oleic acid decyl ester, hexyl laurate, oleyl
oleate, decyl oleate, capric acid esters of saturated fat alcohols of chain length
C
12-C
18; solutions of esters of dicarboxylic acids, such as dibutyl phthalate, diisopropyl
isophthalate, adipic acid diisopropyl ester, di-n-butyl adipate or also solutions
of esters of aliphatic acids, e.g. glycols, It may be advantageous for a dispersing
agent to be additionally present, such as one known from the pharmaceutical or cosmetic
industry. Examples are 2-pyrrolidone, 2-(N-alkyl)pyrrolidone, acetone, polyethylene
glycol and the ethers and esters thereof, propylene glycol or synthetic triglycerides.
[0100] The oily solutions include e.g. vegetable oils such as olive oil, groundnut oil,
sesame oil, pine oil, linseed oil or castor oil. The vegetable oils may also be present
in epoxidised form. Paraffins and silicone oils may also be used.
[0101] A pour-on or spot-on formulation generally contains 1 to 98.9 % by weight of a compound
of formula (I), 0.1 to 80 % by weight of dispersing agent and 1 to 98.9 % by weight
of solvent. The pour-on or spot-on method is especially advantageous for use on herd
animals such as cattle, horses, sheep or pigs, in which it is difficult or time-consuming
to treat all the animals orally or by injection. Because of its simplicity, this method
can of course also be used for all other animals, including individual domestic animals
or pets, and is greatly favoured by the keepers of the animals, as it can often be
carried out without the specialist presence of the veterinarian.
[0102] Whereas it is preferred to formulate commercial products as concentrates, the end
user will often use dilute formulations. However, this depends on the mode of administration.
Orally administered products are most often used in diluted form or as feed additives,
wheres commercial pour-on and spot-on formulations are normally ready-to-use concentrates.
Such compositions may also contain further additives, such as stabilisers, anti-foaming
agents, viscosity regulators, binding agents or tackifiers, as well as other active
ingredients, in order to achieve special effects.
[0103] Insecticidal and acaricidal compositions of this type, which are used by the end
user, similarly form a constituent of the present invention.
[0104] In each of the processes according to the invention for pest control or in each of
the pest control compositions according to the invention, the active ingredients of
formula (I) can be used in all of their steric configurations or in mixtures thereof.
[0105] The invention also includes a method of prophylactically protecting animals, especially
productive livestock, domestic animals and pets, against parasitic helminths, which
is characterised in that the active ingredients of formula (I) or the active ingredient
formulations prepared therefrom are administered to the animals as an additive to
the feed, or to the drinks or also in solid or liquid form, orally or by ejection
or parenterally. The invention also includes the compounds of formula (I) according
to the invention for usage in one of the said processes.
[0106] The following examples serve merely to illustrated the intention without restricting
it, the term active ingredient representing any substance as described in the preparation
examples.
[0107] In particular, preferred formulations are made up as follows:
(% = percent by weight)
Formulation examples
[0108]
| 1. |
Granulate |
a) |
b) |
| (i) |
active ingredient |
5% |
10 % |
| |
kaolin |
94% |
- |
| |
highly dispersed silicic acid |
1 % |
- |
| |
attapulgite |
- |
90 % |
[0109] The active ingredient is dissolved in methylene chloride, sprayed onto the carrier
and the solvent subsequently concentrated by evaporation under vacuum. Granulates
of this kind can be mixed with the animal feed.
| (ii) |
active ingredient |
3 % |
| |
polyethylene glycol (mw 200) |
3 % |
| |
kaolin |
94 % |
(mw = molecular weight)
[0110] The finely ground active ingredient is evenly applied in a mixer to the kaolin which
has been moistened with polyethylene glycol. In this way, dust-free coated granules
are obtained.
2. Tablets or boli
[0111]
| I |
active ingredient |
33.00 % |
| |
methylcellulose |
0.80 % |
| |
silicic acid, highly dispersed |
0.80 % |
| |
corn starch |
8.40 % |
| II |
lactose, cryst. |
22.50 % |
| |
corn starch |
17.00% |
| |
microcyst. cellulose |
16.50 % |
| |
magnesium stearate |
1.00% |
- I Methyl cellulose is stirred into water. After the material has swollen, silicic
acid is stirred in and the mixture homogeneously suspended. The active ingredient
and the corn starch are mixed. The aqueous suspension is worked into this mixture
and kneaded to a dough. The resulting mass is granulated through a 12 M sieve and
dried.
- II All 4 excipients are mixed thoroughly.
- III The preliminary mixes obtained according to I and II are mixed and pressed into
tablets or boli.
3. Injectables
A. Oily vehicle (slow release)
[0112]
| (i) |
active ingredient 0.1-1.0 g |
| |
groundnut oil ad 100 ml |
| (ii) |
active ingredient 0.1-1.0 g |
| |
sesame oil ad 100 ml |
[0113] Preparation: The active ingredient is dissolved in part of the oil whilst stirring
and, if required, with gentle heating, then after cooling made up to the desired volume
and sterile-filtered through a suitable membrane filter with a pore size of 0.22 µm.
B Water-miscible solvent (average rate of release)
[0114]
| (i) |
active ingredient 0.1-1.0 g |
| |
4-hydroxymethyl-1,3-dioxolane (glycerol formal) 40 g |
| |
1,2-propenediol ad 100 ml |
| (ii) |
active ingredient 0.1-1.0 g |
| |
glycerol dimethyl ketal 40 g |
| |
1,2-propanediol ad 100 ml |
[0115] Preparation: The active ingredient is dissolved in part of the solvent whilst stirring,
made up to the desired volume and sterile-filtered through a suitable membrane filter
with a pore size of 0.22 µm.
C. Aqueous solubilisate (rapid release)
[0116]
| (i) |
active ingredient 0,1-1,0 g |
| |
polyethoxylated castor oil (40 ethylene oxide units) 10 g |
| |
1,2-propanediol 20 g |
| |
benzyl alcohol 1 g |
| |
aqua ad inject. ad 100 ml |
| (ii) |
active ingredient 0.1-1.0 g |
| |
polyethoxylated sorbitan monooleate (20 ethylene oxide units) 8 g |
| |
4-hydroxymethyl-1,3-dioxolane (glycerol formal) 20 g |
| |
benzyl alcohol 1 g |
| |
aqua ad inject. ad 100 ml |
[0117] Preparation: The active ingredient is dissolved in the solvents and the surfactant,
and made up with water to the desired volume. Sterile filtration through an appropriate
membrane filter of 0.22 µm pore size.
4. Pour on
[0118]
| (i) |
active ingredient |
5 g |
| |
isopropyl myristate |
10 g |
| |
isopropanol |
ad 100 ml |
| (ii) |
active ingredient |
2 g |
| |
hexyl laureate |
5 g |
| |
medium-chained triglyceride |
15 g |
| |
ethanol |
ad 100 ml |
| (iii) |
active ingredient |
2 g |
| |
oleyl oleate |
5 g |
| |
N-methyl-pyrrolidone |
40 g |
| |
isopropanol |
ad 100 ml |
5. Spot on
[0119]
| (i) |
active ingredient |
0-15 g |
| |
diethyleneglycol monoethylether |
ad 100 ml |
| (ii) |
active ingredient |
10-15 g |
| |
octyl palmitate |
10 g |
| |
isopropanol |
ad 100 ml |
| (iii) |
active ingredient |
10-15 g |
| |
isopropanol |
20 g |
| |
benzyl alcohol |
ad 100 ml |
6. Spray on
[0120]
| (i) |
active ingredient |
1 g |
| |
isopropanol |
40 g |
| |
propylene carbonate |
ad 100 ml |
| (ii) |
active ingredient |
1 g |
| |
propylene glycol |
10 g |
| |
isopropanol |
ad 100 ml |
[0121] The aqueous systems may also preferably be used for oral and/or intraruminal application.
The compositions may also contain further additives, such as stabilisers, e.g. where
appropriate epoxidised vegetable oils (epoxidised coconut oil, rapeseed oil, or soybean
oil); antifoams, e.g. silicone oil, preservatives, viscosity regulators, binders,
tackifiers, as well as fertilisers or other active ingredients to achieve special
effects.
[0122] Further biologically active substances or additives, which are neutral towards the
compounds of formula (I) and do not have a harmful effect on the host animal to be
treated, as well as mineral salts or vitamins, may also be added to the described
compositions.
[0123] The following examples serve to illustrate the invention. The letter 'h' stands for
hour. The starting materials are known and partially commercially available or may
be produced in analogy to methods known per se.
[0124] Analysis of the purified samples is in each case done using a Waters Autopurification
(HPLC/MS) system with a reversed phase column (Daisogel SP-120-ODS-AP 5µm, 150X3mm)
from Bischoff, Leonberg, Germany. The samples are characterized by m/z and retention
time. The above-given retention times relate in each case to the use of a solvent
system comprising two different solvents, solvent A: H
2O + 0.01% HCOOH, and solvent B: CH
3CN + 0.01% HCOOH). Said two solvents A and B are employed at a flow rate of 2.00 ml/min
with a time-dependent gradient as given in the Table:
| Time [min] |
A [%] |
B [%] |
| 0.5 |
10 |
90 |
| 1.0 |
26 |
74 |
| 1.5 |
40 |
60 |
| 2.0 |
53 |
47 |
| 2.5 |
64 |
36 |
| 3.0 |
74 |
26 |
| 3.5 |
81 |
19 |
| 4.0 |
87 |
13 |
| 4.25 |
90 |
10 |
| 4.5 |
92 |
8 |
| 4.75 |
93 |
7 |
| 5.0 |
94 |
6 |
| 5.5 |
95 |
5 |
| 6.5 |
95 |
5 |
Example 1
[0125] This example illustrates the preparation of 5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic
acid (2,2,-trifluoro-ethyl)-amide. (Compound 1.8 in Table-1)
[0126] Step A: 3,3,3-Trifluoropropene (3.2 g), potassium carbonate (4.6 g) and bis-(triphenylphosphine)-palladium
chloride (0.2 g) is added to a solution of 3,5-dichlorophenylboronic acid in THF (20
ml) under nitrogen. After 3 hours at reflux the reaction is quenched with ethyl acetate
(50 ml) and water (50 ml). The organic phase is then extracted with water and with
a saturated aqueous solution of NaCl, dried over Na
2SO
4 and concentrated
in vacuo. The crude product is purified on silica gel (35x45 mm) using heptane (150 ml) as
eluant to yield 1,3-dichloro-5-(1-trifluoromethyl-vinyl)-benzene (2.7 g), as a colorless
oil. MS (HPLC/MS): no ionisation. Retention time: 5.10 min.
[0127] Step B: Ethylene glycol (2.18 ml) and p-toluenesulfonic acid (0.74 g) is added to a solution
of 2-brom-3-methyl-5-formylthiophene (4.0 g) in toluene (98 ml) in a Dean-Stark apparatus.
After 18 hours at reflux, the reaction is quenched with water. The organic phase is
separated and the aqueous phase is extracted three times with ethyl acetate. The combined
organic phases are dried over Na
2SO
4 and concentrated
in vacuo. The crude product is purified on a semi-preparative HPLC to yield 2-(5-bromo-4-methyl-thiophen-2-yl)-[1,3]dioxolane
(4.04 g) as a yellow oil. MS (HPLC/MS): 250 (MH
+). Retention time: 4.02 min.
[0128] Step C: BuLi (5.78 ml, 2.5M in THF) is added to a solution of 2-(5-bromo-4-methyl-thiophen-2-yl)-[1,3]dioxolane
(3.0 g) in THF (120 ml) at -78°C. After 1 hour at -78°C, CO
2 is gently bubbled through the reaction solution for 1 hour. A saturated solution
of ammonium chloride (48 ml) is then added and the reaction is slowly warmed up to
room temperature. HCl (1N) is added until pH = 1 is reached and the reaction mixture
is extracted three times with ethyl acetate. The combined organic phases are dried
over Na
2SO
4 and concentrated
in vacuo. The crude product is purified on a semi-preparative HPLC to yield 5-[1,3]dioxolan-2-yl-3-methyl-thiophene-2-carboxylic
acid (957 mg) as a yellowish solid. MS (HPLC/MS): 215 (MH
+). Retention time: 2.28 min.
[0129] Step D: Pyridine (0.90 ml) and thionyl chloride (0.54 ml) is added to a solution of 5-[1,3]dioxolan-2-yl-3-methyl-thiophene-2-carboxylic
acid (400 mg) in THF (9 ml). After 20 hours at room temperature, the reaction mixture
is concentrated
in vacuo. The crude product is dissolved in dichloromethane (6 ml) and added to a solution
of 3,3,3-trifluoroethylamine (0.28 g) and DIPEA (N,N-diisopropylethylamine, 0.52 ml)
in dichloromethane (6 ml). After 1 hour at room temperature, the reaction is quenched
with a saturated solution of NaHCO
3. The reaction mixture is extracted three times with dichloromethane. The combined
organic phases are extracted with water and with a saturated aqueous solution of NaCl,
dried over Na
2SO
4 and concentrated
in vacuo to yield 5-[1,3]dioxolan-2-yl-3-methyl-thiophene-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide
(491 mg) as a brown oil. The crude product obtained is used without further purification.
MS (HPLC/MS): 296 (MH
+). Retention time: 2.85 min.
[0130] Step E: HCl (2N, 4 ml) is added to a solution of 5-[1,3]dioxolan-2-yl-3-methyl-thiophene-2-carboxylic
acid (2,2,2-trifluoro-ethyl)-amide (450 mg) in acetone (10 ml). After 4 hours at 50°C
and one night at room temperature, the reaction is quenched with water. The reaction
mixture is extracted three times with ethyl acetate. The combined organic phases are
dried over Na
2SO
4 and concentrated
in vacuo. The crude product is purified on a semi-preparative HPLC to yield 5-formyl-3-methyl-thiophene-2-carboxylic
acid (2,2,2-trifluoro-ethyl)-amide (196 mg) as a yellowish oil. MS (HPLC/MS): 252
(MH
+). Retention time: 2.54 min.
[0131] Step F: Sodium acetate (90 mg) is added to a solution of hydroxylamine hydrochloride (60
mg) and 5-formyl-3-methyl-thiophene-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide
(190 mg) in THF (5 ml), water (1 ml) and DMSO (1 ml). After 3 hours at room temperature,
the reaction is quenched with water. The reaction mixture is extracted three times
with ethyl acetate. The combined organic phases are dried over Na
2SO
4 and concentrated
in vacuo to yield 5-(hydroxyimino-methyl)-3-methyl-thiophene-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide.
The crude product obtained (206 mg, yellowish oil) is used without further purification.
MS (HPLC/MS): 267 (MH
+). Retention time: 2.56 min and 2.64 min (two diastereoisomers).
[0132] Step G: Chlorox (4%, 1.02 ml) and NaOH (1N, 0.1 ml) are premixed and then added to a solution
of 5-(hydroxyimino-methyl)-3-methyl-thiophene-2-carboxylic acid (2,2,2-trifluoroethyl)-amide
(200 mg) and 1,3-dichloro-5-(1-trifluoromethyl-vinyl)-benzene (170 mg, example 1,
Step A) in THF (3 ml) and diethyl ether (3 ml) at 5°C. The cold bath is then removed.
After 21 hours, water is added and the reaction mixture is extracted three times with
ethyl acetate. The organic phases are combined, dried over Na
2SO
4 and concentrated
in vacuo. The crude product is purified on a semi-preparative HPLC to yield 5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic
acid (2,2,2-trifluoro-ethyl)-amide (56 mg) as light yellow oil. MS (HPLC/MS): 505
(MH
+). Retention time 4.38 min.
Example 2
[0133] This example illustrates the preparation of 4-{5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophen-2-yl}-pyridine.
(Compound 1.45 in Table 1)
[0134] Step A: Acetyl chloride (7.09 g) is added to a suspension of AlCl
3 (11.53 g) in dichloromethane (310 ml) at 0°C. After 45 minutes at 0°C, 2-bromo-3-methylthiophene
(5.0 g) is added dropwise. After 1 hour at 0°C, the reaction is quenched by added
water (100 ml). The mixture is extracted three times with dichloromethane. The organic
phases are combined, dried over MgSO
4 and concentrated
in vacuo. The crude product is purified by chromatography on silica gel (180 g) eluting with
a mixture of ethyl acetate and heptane (1:6) to yield 1-(5-bromo-4-methyl-thiophen-2-yl)-ethanone
(3.5 g) as a brown solid.
[0135] Step B: LiH (2.06 g) is added to a solution of 3',5'-dichloro-2,2,2-trifluoroacetophenone
(48.0 g) and 1-(5-bromo-4-methyl-thiophen-2-yl)-ethanone (30.3 g) in THF (1000 ml).
After 2 hours at 60°C MTBE is added (300 ml) and the reaction mixture is poured onto
water (500 ml) at 0°C. The organic phase is extracted with water and a saturated aqueous
solution of NaCl, dried over Na
2SO
4 and concentrated
in vacuo to yield 71.2 g of 1-(5-bromo-4-methyl-thiophen-2-yl)-3-(3,5-dichloro-phenyl)-,4,4-4-trifluoro-3-hydroxy-butan-1-one.
The crude product is used without further purification.
[0136] Step C: Trifluoroacetic anhydride (27.1 ml) is added dropwise to a solution of 1-(5-bromo-4-methyl-thiophen-2-yl)-3-(3,5-dichloro-phenyl)-4,4,4-trifluoro-3-hydroxy-butan-1-one
(63.9 g) and triethylamine (38.5 ml) in dichloromethane (900 ml). After 2 hours at
room temperature, the reaction is diluted with water. The reaction mixture is extracted
three times with ethyl acetate. The combined organic phases are washed once with a
saturated aqueous solution of NaHCO
3 and once with a saturated aqueous solution of NaCl, dried over Na
2SO
4 and concentrated
in vacuo to yield 72.3 g of (
E/
Z)-1-(5-bromo-4-methyl-thiophen-2-yl)-3-(3,5-dichloro-phenyl)-4,4,4-trifluoro-but-2-en-1-one.
The crude product is used without further purification.
[0137] Step D: NaOH (13.6 g) and hydroxylamine hydrochloride (9.8 g) are added to a solution of
(E/Z)-1-(5-bromo-4-methyl-thiophen-2-yl)-3-(3,5-dichloro-phenyl)-4,4,4-trifluoro-but-2-en-1-one
(62.7 g) in ethanol (500 ml). After 2 hours at room temperature the reaction mixture
is concentrated
in vacuo. Ethyl acetate is added to the residue. The organic phase is extracted with a saturated
aqueous solution of NaCl, dried over Na
2SO
4 and concentrated
in vacuo. The crude product is purified by chromatography on silica gel (2000 g) eluting with
a mixture of heptane and ethyl acetate (100:0 to 95:5) to yield 3-(5-bromo-4-methyl-thiophen-2-yl)-5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazole
(41.6 g, compound 1.9 in Table 1) as a brown solid.
[0138] Step E: Pyridine-4-boronic acid (30 mg) is added to a solution of 3-(5-bromo-4-methyl-thiophen-2-yl)-5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazole
(100 mg), K
2CO
3 (90 mg) and Pd(PPh
3)
4 (20 mg) in a mixture of THF and water (0.4 ml, 9:1). After 22 hours at 70°C, the
reaction is quenched with water and extracted three times with ethyl acetate. The
organic phases are combined, dried over MgSO
4 and concentrated
in vacuo. The crude product is purified on a semi-preparative HPLC to yield 4-{5-[5-(3,5-dichlorophenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophen-2-yl}-pyridine
(40 mg) as a colorless oil. MS (HPLC/MS): 457 (MH+). Retention time: 5.20 min.
Example 3
[0139] This example illustrates the preparation of 1-benzyl-4-{5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophen-2-yl}-1H-[1,2,3]triazole.
(Compound 1.46 in Table 1)
[0140] Step A: Trimethylsilylacetylene (16 ml) is added to a solution of 1-(5-bromo-4-methyl-thiophen-2-yl)-ethanone
(16.9 g, example 1, step A), Pd(PPh
3)
2Cl
2 (3.78 g), Cul (1.46 g) and triethylamine (16 ml) in DMF (15 ml). After 3 hours at
room temperature, the reaction is quenched with water and extracted three times with
ethyl acetate. The organic phases are combined, dried over Na
2SO
4 and concentrated
in vacuo. The crude product is purified by filtration over a plug of silica gel eluting with
dichloromethane to yield 1-(4-methyl-5-trimethylsilanylethynyl-thiophen-2-yl)-ethanone
(18.2 g) as yellow solid. The compound is used without further purification.
[0141] Step B: LiH (1.72 g) is added to a solution of 3',5'-dichloro-2,2,2-trifluoroacetophenone
(26.6 g) and 1-(4-methyl-5-trimethylsilanylethynyl-thiophen-2-yl)-ethanone (18.2 g)
in THF (100 ml). After 30 minutes at 60°C MTBE is added (200 ml) and the reaction
mixture is poured onto water (30 ml) at 5°C. The organic phase is extracted with water
and a saturated aqueous solution of NaCl, dried over Na
2SO
4 and concentrated
in vacuo to yield 3-(3,5-dichloro-phenyl)-4,4,4-trifluoro-3-hydroxy-1-(4-methyl-5-trimethylsilanylethynyl-thiophen-2-yl)-butan-1-one
(20.7 g). The crude product is used without further purification.
[0142] Step C: Trifluoroacetic anhydride (8.46 ml) is added dropwise to a solution of 3-(3,5-dichlorophenyl)-4,4,4-trifluoro-3-hydroxy-1-(4-methyl-5-trimethylsilanylethynyl-thiophen-2-yl)-butan-1-one
(20.7 g) and triethylamine (12.0 ml) in dichloromethane (40 ml). After 3 hours at
room temperature, the reaction is diluted with a saturated aqueous solution of NaHCO
3 and extracted three times with dichloromethane. The combined organic phases are dried
over Na
2SO
4 and concentrated
in vacuo to yield (
E/
Z)-3-(3,5-dichloro-phenyl)-4,4,4-trifluoro-1-(4-methyl-5-trimethylsilanylethynyl-thiophen-2-yl)-but-2-en-1-one
(17.6 g) as a brown oil. The crude product is used without further purification.
[0143] Step D: NaOH (3.66 g) and hydroxylamine hydrochloride (2.65 g) are added to a solution of
(
E/
Z)-3-(3,5-dichloro-phenyl)-4,4,4-trifluoro-1-(4-methyl-5-trimethylsilanylethynyl-thiophen-2-yl)-but-2-en-1-one
(17.6 g) in ethanol (120 ml). After 2 hours at room temperature the reaction is quenched
with a saturated aqueous solution of NaHCO
3 and extracted three times with dichloromethane. The combined organic phases are dried
over Na
2SO
4 and concentrated
in vacuo. The crude product is purified on a semi-preparative HPLC to yield 5-(3,5-dichloro-phenyl)-3-(5-ethynyl-4-methyl-thiophen-2-yl)-5-trifluoromethyl-4,5-dihydro-isoxazole
(6.32 g) as a red solid. Melting point 105°C - 107°C.
[0144] Step E: Cul (47 mg) is added to a solution of benzylazide (33 mg), DIPEA (1.05 ml) and 5-(3,5-dichloro-phenyl)-3-(5-ethynyl-4-methyl-thiophen-2-yl)-5-trifluoromethyl-4,5-dihydro-isoxazole
(100 mg) in DMF (2.0 ml). After 16 hours at room temperature, the reaction is quenched
with a saturated aqueous solution of NaHCO
3 and extracted three times with ethyl acetate. The combined organic phases are dried
over Na
2SO
4 and concentrated
in vacuo. The crude product is purified on a semi-preparative HPLC to yield 1-benzyl-4-{5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophen-2-yl}-1H-[1,2,3]triazole
(34 mg) as a yellowish foam. MS (HPLC/MS): 537 (MH+). Retention time: 5.04 min.
Example 4
[0145] This example illustrates the preparation of 5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic
acid [(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-amide. (Compound 1.28 in Table 1)
[0146] Step A: DIPEA (15 ml) is added to a solution of N-(
tert-butoxycarbonyl)glycine (5.0 g), PYBOP (benzotriazol-1-yl-oxytripyrrolidinophosphonium
hexafluorophosphate, 16.3 g) and 2,2,2-trifluorethylamine (2.47 ml) in dichloromethane
(48 ml). After 24 hours at room temperature, the reaction is quenched with water and
extracted three times with dichloromethane. The combined organic phases are washed
with HCl (2M), Na
2CO
3 (1 M) and a saturated aqueous solution of NaCl, dried over MgSO
4 and concentrated
in vacuo. The crude product is purified by column chromatography (450 g) eluting with a mixture
of ethyl acetate and hexane (2:3 to 3:2) to yield [(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-carbamic
acid
tert-butyl ester (3.89 g).
[0147] Step B: Trifluoracetic acid (23.4 ml) is added dropwise to a solution of [(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-carbamic
acid
tert-butyl ester (3.89 g) in dichloromethane (75 ml). After 18 hours at room temperature,
the reaction mixture is concentrated
in vacuo. The crude oil is purified by crystallization in diethylether to yield (2,2,2-trifluoro-ethylcarbamoyl)-methyl-ammonium
trifluoroacetate (4.12 g) as a white solid.
[0148] Step C: Ethylmagnesium chloride (10.9 ml, 2M in THF) is added over 30 minutes to a solution
of 3-(5-bromo-4-methyl-thiophen-2-yl)-5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazole
(10.0 g, Example 2, step D) in THF (15 ml) at 0°C. After 1 hour at room temperature,
a solution of ethylcyanoformate (2.81 g) in THF (15 ml) is added to the reaction mixture.
After 40 minutes, the reaction is quenched with a saturated aqueous solution of NH
4Cl in water. The mixture is extracted three times with MTBE. The organic phases are
combined, dried over Na
2SO
4 and concentrated
in vacuo. The crude product is purified on a semi-preparative HPLC to yield 5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic
acid ethyl ester (5.6 g) as a yellowish oil.
[0149] Step D: LiOH (3.2 g) is added to a solution of 5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic
acid ethyl ester (9.88 g) in a mixture of THF and water (240 ml, 9:1). After 16 hours
at room temperature, LiOH (1.05 g) and THF (150 ml) was added. The reaction mixture
was heated at 50°C for 10 hours. HCl (2N) was added to the reaction mixture until
pH 1-2 was obtained. The mixture was then extracted three times with ethyl acetate.
The organic phases were combined, washed with water and a saturated aqueous solution
of NaCl, dried over Na
2SO
4 and concentrated in
vacuo to yield 5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic
acid (9.3 g) as brown resin. The crude product is used without further purification.
[0150] Step E: DIPEA (0.246 ml) is added to a solution of (2,2,2-trifluoro-ethylcarbamoyl)-methylammonium
trifluoroacetate (0.170 g, Example 4, step B), PYBOP (0.270 g), and 5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic
acid (0.2 g) in dichloromethane (3 ml) at 0°C. After 30 minutes at room temperature
the reaction is quenched with water and extracted three times with dichloromethane.
The combined organic phases are washed with a saturated aqueous solution of NaCl and
a saturated aqueous solution of NaHCO
3, dried over Na
2SO
4 and concentrated
in vacuo. The crude product is purified on a semi-preparative reversed phase HPLC to yield
5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic
acid [(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-amide (8.73 g) as a beige foam. MS
(HPLC/MS): 562 (MH+). Retention time: 3.94 min.
[0151] The substances named in the following Table 1 are prepared analogously to the above-described
methods. The compounds are of formula

wherein the meaning of A is given Table 1.
[0152] The following physical data are obtained according to the above-described HPLC/MS
characterization process. The values of the melting point are indicated in °C.
[0153] The substances named in the following Table 2 are prepared analogously to the above-described
methods. The compounds are of formula

wherein the meaning of A is given Table 2.
[0154] The following physical data are obtained according to the above-described HPLC/MS
characterization process. The values of the melting point are indicated in °C.
Biological Examples:
1. Activity in vitro against Ctenocephalides felis (Cat flea).
[0155] A mixed adult population of fleas is placed in a suitably formatted 96-well plate
allowing fleas to access and feed on treated blood via an artificial feeding system.
Fleas are fed on treated blood for 24 hours, after which the compound effect is recorded.
Insecticidal activity is determined on the basis of the number of dead fleas recovered
from the feeding system. Compound 1.1, 1.4, 1.5, 1.6, 1.7, 1.8, 1.13, 1.14, 1.19,
1.20, 1.21, 1.23, 1.25, 1.26, 1.27, 1.28, 1.29, 1.30, 1.31, 1.32, 1.33, 1.35, 1.47,
1.48, 1.49, 1.50, 1.52, 1.54, 1.57, 1.58, 1.59, 1.60, 1.61, 1.62, 1.68, 1.69, 1.70,
1.76, 1.78, 1.84, 1.86, 1.87, 1.88, 1.89, 1.90, 1.91, 1.92, 1.93, 1.99, 1.102, 1.104,
1.105, 1.106, 1.107, 1.108, 1.109, 1.110, 1.112, 1.113, 1.114, 2.1, 2.2, 2.3, 2.4
and 2.5 showed more than 80% (EC
80) efficacy at 100ppm.
2. Activity in vitro against Rhipicephalus sanguineus (Dog tick).
[0156] A clean adult tick population is used to seed a suitably formatted 96-well plate
containing the test substances to be evaluated for antiparasitic activity. Each compound
is tested by serial dilution in order to determine its minimal effective dose (MED).
Ticks are left in contact with the test compound for 10 minutes and are then incubated
at 28°C and 80% relative humidity for 7 days, during which the test compound effect
is monitored. Acaricidal activity is confirmed if adult ticks are dead.
[0157] In this test the following examples showed more than 80% (EC
80) efficacy at 640ppm: 1.1, 1.8, 1.13, 1.14, 1.19, 1.21, 1.23, 1.27, 1.28, 1.29, 1.30,
1.31, 1.32, 1.33, 1.35, 1.47, 1.48, 1.49, 1.58, 1.59, 1.60, 1.62, 1.63, 1.72, 1.75,
1.85, 1.90, 1.104, 1.108, 1.109, 1.112, 2.2, 2.3, 2.4 and 2.5.
3. Activity in vivo against Rhipicephalus sanguineus nymphs on Mongolian gerbils Meriones unguiculatus) (spray application)
[0158] On day 0, gerbils are treated with the test compound at a given dose by spray application.
On day +1 (+2), the animals are infested with nymphs of
R.sanguineus. Ticks are left on the animals until full repletion. Seven days after infestation
nymphs dropped off fully engorged are collected and counted. Efficacy in killing is
expressed as a tick number reduction in comparison with a placebo treated group, using
the Abbot's formula.
[0159] In this test the following examples showed more than 80% (EC
80) efficacy at the dose indicated in table 3.
Table 3:
| Compound No. |
Dose mg/kg |
Efficacy in killing % |
| 1.8 |
32 |
80 |
| 1.21 |
32 |
98 |
| 1.28 |
10 |
96 |
| 1.29 |
100 |
92 |
| 1.31 |
32 |
100 |
| 1.32 |
100 |
84 |
| 1.35 |
10 |
82 |
| 1.48 |
10 |
95 |
| 1.49 |
3.2 |
85 |
| 2.4 |
10 |
90 |
| 2.5 |
10 |
90 |
4. Activity in vivo against Rhipicephalus sanguineus nymphs or Mongolian gerbils (Meriones unguiculatus) (per oral application)
[0160] One day before treatment, gerbils are infested with nymphs of
R.sanguineus. On day 0, the animals are treated orally by gavage with the test compound formulated
at a given dose. Ticks are left on the animals until full repletion. Seven days after
infestation nymphs dropped off fully engorged are collected and counted. Efficacy
in killing is expressed as a tick number reduction in comparison with a placebo treated
group, using the Abbot's formula.
[0161] In this test the following examples showed more than 90% (EC
90) efficacy at 100 mg/kg: 1.28, 1.31, 1.48, 1.49, 1.58, 2.3, 2.4 and 2.5.
5. Activity in vivo against Ctenocephalides felis (cat flea) on Mongolian gerbils (Meriones unguiculatus) (per oral application)
[0162] On day 0, gerbils are treated orally by gavage with the test compound formulated
at a given dose. Immediately after treatment, they are infested with a mixed adult
population of cat fleas. Evaluation of efficacy is performed 48h infestation buy counting
the lumbers of live fleas recovered from the gerbils. Efficacy is expressed as comparison
with a placebo treated group using the Abbot's formula.
[0163] In this test the following examples showed more than 90% (EC
90) efficacy at 100 mg/kg: 1.28, 1.31, 1.48, 1.49, 2.3 and 2.4.
1. A compound of formula

including all geometric and stereoisomers, N-oxides, and salts thereof, wherein
X, is S(O)
m, O or NR
5' and X
1 and X
2 are each independently of the other CR
3' or N,
n is an integer from 0 to 4; m is an integer from 0 to 2;
B
1, B
2 and B
3 are each independently selected from the group consisting of CR
2' and N;
each R
2' is independently of the other H or R
2;
each R
3' is independently of the other H or R
3;
R
1 is C
1-C
6-alkyl, C
2-C
6-alkenyl, C
2-C
6-alkynyl, C
3-C
6-cycloalkyl, C
4-C
7-alkylcycloalkyl or C
4-C
7-cycloalkylalkyl, each unsubstituted or substituted with one or more substituents
independently selected from R
4;
R
4 is halogen, C
1-C
6-alkyl, C
1-C
6-alkoxy, C
1-C
6-alkylthio, C
1-C
6-alkylsulfinyl, C
1-C
6alkylsulfonyl, cyano or nitro;
each R
2 is independently halogen, C
1-C
6-alkyl, C
1-C
6-haloalkyl, C
1-C
6-alkoxy, C
1-C
6-haloalkoxy, C
1-C
6-alkylthio, C
1-C
6-haloalkylthio, C
1-C
6-alkylsulfinyl, C
1-C
6-haloalkylsulfinyl, C
1-C
6-alkylsulfonyl, C
1-C
6-haloalkylsulfonyl, N-mono- or N,N-di-C
1-C
6-alkylamino, C
1-C
6 alkoxycarbonyl, cyano (-CN) or nitro (-NO
2);
each R
3 is independently H, halogen, C
1-C
6-alkyl, C
1-C
6-haloalkyl, C
3-C
6-cycloalkyl, C
3-C
6-halocycloalkyl, C
1-C
6-alkoxy, C
1-C
6-haloalkoxy, C
1-C
6-alkylthio, C
1-C
6-haloalkylthio, C
1-C
6-alkyl-sulfinyl, C
1-C
6-haloalkylsulfinyl, C
1-C
6-alkylsulfonyl, C
1-C
6-haloalkylsulfonyl, amino, N-mono- or N,N-di-C
1-C
6-alkylamino, C
1-C
6-alkoxycarbonyl, cyano, nitro or unsubstituted or halogen-, C
1-C
6-alkyl-, C
1-C
6-haloalkyl-, C
1-C
6-alkoxy-, C
1-C
6-haloalkoxy-, amino-, cyano- or nitro-substituted phenyl, pyridyl or pyrimidyl;
Z is halogen, a radical Q or a group -C(W)-NR
5R
6;
Q is a 5- or 6-membered heterocyclic ring or a C
6-C
10-carbocyclic ring system or a 8-, 9- or 10-membered fused hetero-bicyclic ring system,
each of them being unsubstituted or
substituted with one or more substituents independently selected from halogen, C
1-C
6-alkyl, C
1-C
6-haloalkyl, C
3-C
6-cycloalkyl, C
3-C
6-halocycloalkyl, C
1-C
6-alkoxy, C
1-C
6-haloalkoxy, C
1-C
6-alkylthio, C
1-C
6-haloalkylthio, C
1-C
6-alkylsulfinyl, C
1-C
6-haloalkylsulfinyl, C
1-C
6-alkylsulfonyl, C
1-C
6-haloalkylsulfonyl, cyano, nitro, amino, N-mono- or N,N-di-C
1-C
4-alkylamino, C
1-C
6-alkoxycarbonyl, sulfonamido, N-mono- or N,N, di-C
1-C
4-alkylsulfonamido, C
1-C
6-alkylcarbonylamino, N-mono- or N,N-di-C
1-C
6-alkylaminocarbonyl, C
2-C
6-alkanoyl, a group -(alk)-C(W')NR
5"R
7, phenyl, benzyl, benzoyl, phenoxy, pyridyl, pyridyl-(alk)-, pyrimidyl and pyrimidyl-(alk),
wherein the phenyl, benzyl, benzoyl, phenoxy, pyridyl and pyrimidyl are each unsubstituted
or substituted by halogen, C
1-C
6-alkyl, C
1-C
6-haloalkyl, C
1-C
6-alkoxy, C
1-C
6-haloalkoxy, cyano, nitro or amino;
(alk) is straight-chain or branched C
1-C
6-alkylene,
W and W' are each independently of the other O or S,
R
5, R
5' and R
5" are each independently of the other H, C
1-C
6-alkyl, C
2-C
6-alkenyl, C
2-C
6-alkynyl, C
3-C
6-cycloalkyl, C
4-C
7-alkylcycloalkyl, C
4-C
7-cycloalkylalkyl, C
1-C
6-alkylcarbonyl or C
1-C
6-alkoxycarbonyl;
R
6 is H; Q', wherein Q' has independently the meaning of Q; or is C
1-C
6-alkyl, C
2-C
6-alkenyl, C
2-C
6-alkynyl, C
3-C
6-cycloalkyl, C
4-C
7-alkylcycloalkyl or C
4-C
7-cycloalkylalkyl, each unsubstituted or substituted by halogen C
1-C
6-alkoxy, C
1-C
6-alkylthio, C
1-C
6-alkylsulfinyl, C
1-C
6-alkylsulfonyl, cyano, nitro, amino, N-mono- or N,N-di-C
1-C
6-alkylamino, C
3-C
6-cycloalkylamino, C
1-C
6-alkoxycarbonyl, C
2-C
6-alkanoyl, C
1-C
6-alkylcarbonylamino, aminocarbonyl, N-mono- or N,N-di-C
1-C
6-alkylaminocarbonyl, a group -C(W')NR
5"R
7 or a radical Q", wherein Q" independently has the meaning of Q; or
R
5 and R
6 together with the N-atom to which they are attached, form a 3- to 7-membered ring
which optionally contains a further heteroatom selected from the group consisting
of N, S and O, and which ring is further unsubstituted or substituted by C
1-C
2-alkyl, C
1-C
2-alkyl, C
1-C
2-alkoxy, halogen, cyano or nitro, and
R
7 is C
1-C
6-alkyl, C
2-C
6-alkenyl, C
2-C
6-alkynyl, C
3-C
6-cycloalkyl, C
4-C
7-alkylcycloalkyl or C
4-C
7-cycloalkylalkyl, which is each unsubstituted or substituted by halogen C
1-C
6-alkoxy, C
1-C
6-alkylthio, C
1-C
6-alkylsulfinyl, C
1-C
6-alkylsulfonyl, cyano, nitro, amino, N-mono- or N,N-di-C
1-C
6-alkylamino, pyridyl, pyrimidyl or thiazolyl, or by pyridyl, pyrimidyl or thiazolyl
being mono- or disubstituted by halogen, cyano, C
1-C
2-alkyl or C
1-C
2-haloalkyl
2. A compound of formula (I) according to claim 1, wherein
X is S(O)m, O or NR5' and X1 and X2 are each independently of the other CR3' or N,
n is an integer from 0 to 4, m is an integer from 0 to 2,
B1, B2 and B3 are each independently selected from the group consisting of CR2' and N; each R2' is independently of the other H or R2;
each R3' is independently of the other H or R3;
R1 is C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C4-C7-alkylcycloalkyl or C4-C7-cycloalkylalkyl, each unsubstituted or substituted with one or more substituents
independently selected from R4;
R4 is halogen, C1-C6-alkyl, C1-C6-alkoxy, C1-C6-alkylthio, C1-C6-alkylsulfinyl, C1-C6-alkylsulfonyl, cyano or nitro;
each R2 is independently halogen, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C6-alkylthio, C1-C6-haloalkylthio, C1-C6-alkylsulfinyl, C1-C6-haloalkylsulfinyl, C1-C6-alkylsulfonyl, C1-C6-haloalkylsulfonyl, N-mono- or N,N-di-C1-C6-alkylamino, C2-C6-alkoxycarbonyl, cyano (-CN) or nitro (-NO2);
each R3 is independently H, halogen, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C-6-alkylthio, C1-C6-haloalkylthio, C1-C6 alkyl-sulfinyl, C1-C6-haloalkylsulfinyl, C1-C6-alkylsulfonyl, C1-C6-haloalkylsulfonyl, amino, N-mono- or N,N-di-C1-C6-alkylamino, C2-C6-alkoxycarbonyl, cyano or nitro;
Z is halogen, a radical Q or a group -C(W)-NR5R6;
Q is a 5- or 6-membered heterocyclic ring, or a C6-C10-carbocyclic ring system or a 8-, 9- or 10-membered fused hetero-bicyclic ring system,
each of them being unsubstituted or substituted with one or more substituents independently
selected from halogen, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C6-alkythio, C1-C6-haloalkylthio, C1-C6-alkylsulfinyl, C1-C6-haloalkylsulfinyl, C1-C6-alkylsulfonyl, C1-C6-haloalkylsulfonyl, cyano, nitro, amino, N-mono- or N,N-di-C1-C6-alkylamino, C1-C6-alkoxycarbonyl, sulfonamido, N-mono- or N,N, di-C1-C6-alkylsulfonamido, C1-C6-alkylcarbonylamino, N-mono- or N,N-di-C1-C6-alkylaminocarbonyl, C2-C6-alkanoyl and unsubstituted or halogen-, C1-C6alkyl-, C1-C6-haloalkyl-, C1-C6-alkoxy-, C1-C6-haloalkoxy-, cyano- or nitro-substituted phenyl, benzyl, benzoyl or phenoxy;
W is O or S,
R5 and R5 are each independently of the other H, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C4-C7-alkylcycloalkyl, C4-C7-cycloalkylalkyl, C2-C6-alkylcarbonyl or C2-C6-alkoxycarbonyl;
R6 is H; Q', wherein Q' independently has the meaning of Q, or is C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C4-C7-alkylcycloalkyl or C4-C7-cycloalkylalkyl, each unsubstituted or substituted by halogen C1-C6-alkoxy, C1-C6-alkylthio, C1-C6-alkylsulfinyl, C1-C6-alkylsulfonyl, cyano, nitro, amino, N-mono- or N,N-di-C1-C4-alkylamino, C3-C6-cycloalkylamino, C2-C6-alkoxycarbonyl, C2-C6-alkanoyl, C2-C6-alkylcarbonylamino, aminocarbonyl, N-mono- or N,N-di-C1C6-alkylaminocarbonyl or a radical Q", wherein Q" independently has the meaning of Q,
or
R5 and R6 together with the N-atom to which they are attached, form a 3- to 7-membered ring
which optionally contains a further heteroatom selected from the group consisting
of N, S and O, and which ring is further unsubstituted or substituted by C1-C2-alkyl, C1-C2-alkyl, C1-C2-alkoxy, halogen, cyano or nitro.
3. A compound according to claim 1 or 2, wherein B1, B2 and B3 are each CR2'.
4. A compound according to any one of claims 1 to 3, wherein X is S(O)m, O or NR5', one of X1 and X2 is CR3' and the other one is N or independently CR3', therein R3' is each independently H or C1-C2-alkyl, R5' is H or C1-C2-alkyl, and m is an integer trom 0 to 2.
5. A compound according to any one of claims 1 to 4, wherein R1 is halo-C1-C3-alkyl, in particular CF3.
6. A compound according to claim 1 or 2 of formula

wherein R
1, R
2, X, X
1, X
2, Z and n are as defined in claim 1.
7. A compound according anyone of claims 1 to 6, wherein Z is a 5- or 6-membered heterocyclic
ring having from 1 to 4, preferably from 1 to 3 same or different heteroatoms selected
from the group consisting of N, O and S, which is further unsubstituted or substituted
by one or more substituents selected from the group consisting of C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-haloalkylthio, C1-C4-alkylsulfinyl, C1-C4-haloalkylsulfinyl, C1-C4-alkylsulfonyl, C1-C4-haloalkylsulfonyl, cyano, nitro, C1-C4-alkoxycarbonyl, sulfonamido, N-mono- or N,N-di-C1-C4-alkylcarbonylamino, C2-C3-alkanoyl and unsubstituted or halogen- or C1-C4-alkyl-substituted phenyl, benzyl, benzoyl and phenol.
8. A compound according to claim 7, wherein Z is a radical Q of formula

wherein (R)
r is 0 to 3 same or different substituents selected from the group consisting of halogen,
C
1-C
2-alkyl, C
1-C
2-haloalkyl, C
1-C
2-alkoxy, C
1-C
2-haloalkoxy, C
1-C
2-haloalkylthio, cyano, nitro, and C
1-C
4-alkoxycarbonyl.
9. A compound according to claim 8, wherein Z is the radical Q-34, wherein r is 0.
10. A compound according anyone of claims 1 to 6, wherein Z is a group -C(O)-NR5R6, wherein R5 is H, C1-C2-alkyl, C2-C4-alkylcarbonyl or C2-C4-alkoxycarbonyl and R6 is C1-C4-alkyl which is substituted by halogen, cyano, nitro or a radical Q' wherein Q' has
the meaning of Q as given in claim 7.
11. A compound according to claim 10, therein R5 is H and R6 is is C1-C4-alkyl which is substituted by halogen or by a radical Q-34 or Q-48 given in claim
7, wherein r is 0.
12. A compound of formula (Ia) according to claim 6, wherein
n is an integer from 1 to 3, R
1 is halogen-substituted C
1-C
3-alkyl, each R
2 is independently selected from the group consisting of halogen, C
1-C
6-haloalkyl, C
1-C
6-haloalkoxy and cyano, X is S(O)
m, O or NR
5', m is an integer from 0 to 2, R
5' is H or C
1-C
2-alkyl, one of X
1 and X
2 is CR
3' and the other one is N or independently CR
3', wherein R
3' is each independently H or C
1-C
2-alkyl, and Z is either
(i) halogen, or
(ii) a radical Q of formula




wherein (R)r is 0 to 3 same or different substituents selected from the group consisting of halogen,
C1-C2-alkyl, C1-C2-haloalkyl, C1-C2-akoxy, C1-C2-haloalkoxy, C1-C2-haloalkylthio, -cyano, nitro, and C1-C4-alkoxycarbonyl, or is
(iii) a group-C(O)-NR5R6, wherein R5 is H, C1-C2-alkyl, C2-C4-alkylcarbonyl or C2-C4-alkoxycarbonyl and R6 is C1-C4-alkyl which is substituted by halogen, cyano, nitro or a radical Q-34, Q-48, Q-49
or Q-50 above, wherein R and r are as defined.
13. A compound of formula (Ia) according to claim 6, wherein
n is an integer from 1 to 3, R1 is CF3, each R2 is independently selected from the group consisting of halogen, C1-C6-haloalkyl, C1-C6 haloalkoxy and cyano, X is S(O)m, wherein m is an integer from 0 to 2, in particular 0, one of X1 and X2 is CR3' and the other one is N or independently CR3', wherein R3' is each independently H or C1-C2-alkyl, and Z is either (ii) the radical Q-34 given in claim 7, wherein r is 0; or
(iii) a group -C(O)-NR5R6, wherein R5 is H and R6 is C1-C4-alkyl which is substituted by halogen or by a radical Q-34 or Q-48 given in claim
7, wherein r is 0.
14. A compound of formula (I) according to claim 1 or 6, wherein Z is a radical -C(W)-NR5R6, R6 is a radical -(alk)-C(W')-NR5"R7, W and W' are each independently O or S, (alk) is straight-chain or branched C1-C4-alkylene, and R5, R5" and R7 are each as defined in claim 1.
15. A compound of formula (Ia) according to claim 6, wherein Z is a radical -C(O)-NR5R6, wherein R5 is H, R6 is a radical -(alk)-C(O)-NR5"R7, (alk) is methylene or 1,2-ethylene, in particular methylene, R5" is H, and R7 is C1-C6-alkyl, which is unsubstituted or substituted by halogen, cyano or pyridyl, or is
C2-C4-alkynyl or C3-C4-cycloalkyl.
16. A compound of formula (I) according to claim 1 or 6, wherein Z is a radical Q, Q is
a radical of formula

r is 1, R is a radical -(alk)-C(W')-NR
5"R
7, (alk) is straight-chain or branched C
1-C
4-alkylene, W' is O or S, and R
5" and R
7 are each as defined in claim 1.
17. A compound of formula (Ia) according to claim 6, wherein Z is a radical Q, Q is a
radical of formula

R is a radical -(alk)-C(O)-NHR
7, (alk) is methylen or 1,2-ethylene, in particular methylene, and R
7 is C
1-C
6-alkyl, which is unsubstituted or substituted by halogen, cyano or pyridyl, or is
C
2-C
4-alkynyl or C
3-C
4-cycloalkyl.
18. A compound of formula (I) according to claim 1, which is
5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic
acid [(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-amide; or
5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic
acid (4-trifluoromethyl-thiazol-2-yl)-amide; or
5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic
acid ethylcarbamoylmethyl-amide; or
5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic
acid prop-2-ynylcarbamoylmethyl-amide; or
5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic
acid [(cyanomethyl-carbamoyl)-methyl]-amide; or
5-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic
acid [(2,2,2-trifluoro-ethylthiocarbamoyl)-methyl]-amide: or
-5-[5-(3,5-bis-trifluoromethyl-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methylthiophene-2-carboxylic
acid [(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-amide; or
5-[5-(3,4,5-trichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic
acid [(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-amide; or
5-[5-(3,5-dichloro-4-fluoro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methylthiophene-2-carboxylic
acid [(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-amide.
19. A compound of formula (I) according to claim 1, which is 5-[5-(3,4,5-trichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic
acid [(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-amide.
20. Composition for the control of parasites, comprising as active ingredient at least
one compound of the formula (1) according to any one of claims 1 to 19, in addition
to a carrier and/or a dispersant.
21. Use of a compound of formula (1) according to any one of claims 1 to 19 in the preparation
of a pharmaceutical composition against parasites in and on warm-blooded animals.
22. Use according to claim 21, wherein the parasites are ectoparasites selected from the
group consisting of flies, fleas, lice, mites and ticks.
23. Use according to claim 21, wherein the parasites are sea lice.
1. Verbindung der Formel

umfassend alle geometrischen und Stereo-Isomere, N-Oxide und Salze davon, wobei
X S(O)
m, O oder NR
5' ist und X
1 und X
2 jeweils unabhängig voneinander CR
3' oder N sind,
n eine ganze Zahl von 0 bis 4 ist; m eine ganze Zahl von 0 bis 2 ist;
B
1, B
2 und B
3 jeweils unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus CR
2' und N;
jeder R
2' unabhängig voneinander H oder R
2 ist;
jeder R
3' unabhängig voneinander H oder R
3 ist;
R
1 C
1-C
6-Alkyl, C
2-C
6-Alkenyl, C
2-C
6-Alkinyl, C
3-C
6-Cycloalkyl, C
4-C
7-Alkylcycloalkyl oder C
4-C
7-Cyloalkylalkyl ist, jeweils unsubstituiert oder substituiert mit einem oder mehreren
Substituenten unabhängig voneinander ausgewählt aus R
4;
R
4 Halogen, C
1-C
6-Alkyl, C
1-C
6-Alkoxy, C
1-C
6-Alkylthio, C
1-C
6-Alkylsulfinyl, C
1-C
6-Alkyl-sulfonyl, Cyano oder Nitro ist;
jeder R
2 unabhängig voneinander Halogen, C
1-C
6-Alkyl, C
1-C
6-Halogenalkyl, C
1-C
6-Alkoxy, C
1-C
6-Halogenalkoxy, C
1-C
6-Alkylthio, C
1-C
6-Halogenalkylthio, C
1-C
6-Alkylsulfinyl, C
1-C
6-Halogenalkylsulfinyl, C
1-C
6-Alkylsulfonyl, C
1-C
6-Halogenalkylsulfonyl, N-mono- oder N,N-di-C
1-C
6-Alkylamino, C
1-C
6-Alkoxycarbonyl, Cyano (-CN) oder Nitro (-NO
2) ist;
jeder R
3 unabhängig voneinander H, Halogen, C
1-C
6-Alkyl, C
1-C
6-Halogenalkyl, C
3-C
6-Cycloalkyl, C
3-C
6-Halogencycloalkyl, C
1-C
6-Alkoxy, C
1-C
6-Halogenalkoxy, C
1-C
6-Alkylthio, C
1-C
6-Halogenalkylthio, C
1-C
6-Alkyl-sulfinyl, C
1-C
6-Halogenalkylsulfinyl, C
1-C
6-Alkylsulfonyl, C
1-C
6-Halogenalkylsulfonyl, Amino, N-mono- oder N,N-di-C
1-C
6-Alkylamino, C
1-C
6-Alkoxycarbonyl, Cyano, Nitro oder unsubstituiertes oder Halogen-, C
1-C
6-Alkyl-, C
1-C
6-Halogenalkyl-, C
1-C
6-Alkoxy-, C
1-C
6-Halogenalkoxy-, Amino-, Cyano- oder Nitro-substituiertes Phenyl, Pyridyl oder Pyrimidyl
ist;
Z Halogen, ein Radikal Q oder eine Gruppe -C(W)-NR
5R
6 ist;
Q ein 5- oder 6-gliedriger heterozyklischer Ring oder ein C
6-C
10-carbozyklisches Ringsystem oder ein 8-, 9- oder 10-gliedrige fusioniertes hetero-bizyklisches
Ringsystem ist, wobei jeder/jedes von diesen unsubstituiert oder substituiert ist
mit einem oder mehreren Substituenten unabhängig voneinander ausgewählt aus Halogen,
C
1-C
6-Alkyl, C
1-C
6-Halogenalkyl, C
3-C
6-Cycloalkyl, C
3-C
6-Halogencycloalkyl, C
1-C
6-Alkoxy, C
1-C
6-Halogenalkoxy, C
1-C
6-Alkylthio, C
1-C
6-Halogenalkylthio, C
1-C
6-Alkylsulfinyl, C
1-C
6-Halogenalkylsulfinyl, C
1-C
6-Alkylsulfonyl, C
1-C
6-Halogenalkylsulfonyl, Cyano, Nitro, Amino, N-mono- oder N,N-di-C
1-C
4-Alkylamino, C
1-C
6-Alkoxycarbonyl, Sulfonamido, N-mono- oder N,N-di-C
1-C
4-Alkylsulfonamido, C
1-C
6-Alkylcarbonylamino, N-mono- oder N,N-di-C
1-C
6-Alkylaminocarbonyl, C
2-C
6-Alkanoyl, eine Gruppe -(alk)-C(W')NR
5"R
7, Phenyl, Benzyl, Benzoyl, Phenoxy, Pyridyl, Pyridyl-(alk)-, Pyrimidyl und Pyrimidyl-(alk)-,
wobei das Phenyl, Benzyl, Benzoyl, Phenoxy, Pyridyl und Pyrimidyl jeweils unsubstituiert
oder substituiert sind mit Halogen, C
1-C
6-Alkyl, C
1-C
6-Halogenalkyl, C
1-C
6-Alkoxy, C
1-C
6-Halogenalkoxy, Cyano, Nitro oder Amino;
(alk) geradkettiges oder verzweigtes C
1-C
6-Alkylen ist,
W und W' jeweils unabhängig voneinander O oder S sind, R
5, R
5' und R
5" jeweils unabhängig voneinander H, C
1-C
6-Alkyl, C
2-C
6-Alkenyl, C
2-C
6-Alkinyl, C
3-C
6-Cycloalkyl, C
4-C
7-Alkylcycloalkyl, C
4-C
7-Cycloalkylalkyl, C
1-C
6-Alkylcarbonyl oder C
1-C
6-Alkoxycarbonyl sind;
R
6 H; Q' ist, wobei Q' unabhängig voneinander die Bedeutung von Q aufweist; oder C
1-C
6-Alkyl, C
2-C
6-Alkenyl, C
2-C
6-Alkinyl, C
3-C
6-Cycloalkyl, C
4-C
7-Alkylcycloalkyl oder C
4-C
7-Cycloalkylalkyl ist, jeweils unsubstituiert oder substituiert mit Halogen C
1-C
6-Alkoxy, C
1-C
6-Alkylthio, C
1-C
6-Alkylsulfinyl, C
1-C
6-Alkylsulfonyl, Cyano, Nitro, Amino, N-mono- oder N,N-di-C
1-C
6-Alkylamino, C
3-C
6-Cycloalkylamino, C
1-C
6-Alkoxycarbonyl, C
2-C
6-Alkanoyl, C
1-C
6-Alkylcarbonylamino, Aminocarbonyl, N-mono- oder N,N-di-C
1-C
6-Alkylaminocarbonyl, einer Gruppe -C(W')NR
5"R
7 oder einem Radikal Q", wobei Q" unabhängig voneinander die Bedeutung von Q aufweist;
oder R
5 und R
6 zusammen mit dem N-Atom, an das sie gebunden sind, einen 3-bis 7-gliedrigen Ring
bilden, der gegebenenfalls ein weiteres Heteroatom ausgewählt aus der Gruppe bestehend
aus N, S und O enthält, und welcher Ring weiter unsubstituiert oder substituiert ist
mit C
1-C
2-Alkyl, C
1-C
2-Alkyl, C
1-C
2-Alkoxy, Halogen, Cyano oder Nitro; und
R
7 C
1-C
6-Alkyl, C
2-C
6-Alkenyl, C
2-C
6-Alkinyl, C
3-C
6-Cycloalkyl, C
4-C
7-Alkylcycloalkyl oder C
4-C
7-Cycloalkylalkyl ist, welches jeweils unsubstituiert oder substituiert ist mit Halogen,
C
1-C
6-Alkoxy, C
1-C
6-Alkylthio, C
1-C
6-Alkylsulfinyl, C
1-C
6-Alkylsulfonyl, Cyano, Nitro, Amino, N-mono- oder N,N-di-C
1-C
6-Alkylamino, Pyridyl, Pyrimidyl oder Thiazolyl, oder mit Pyridyl, Pyrimidyl oder Thiazolyl,
das mono- oder di-substituiert ist mit Halogen, Cyano, C
1-C
2-Alkyl oder C
1-C
2-Halogenalkyl.
2. Verbindung der Formel (I) nach Anspruch 1, wobei
X S(O)m, O oder NR5' ist und X1 und X2 jeweils unabhängig voneinander CR3' oder N sind,
n eine ganze Zahl von 0 bis 4 ist; m eine ganze Zahl von 0 bis 2 ist;
B1, B2 und B3 jeweils unabhängig voneinander ausgewählt sind aus der Gruppe bestehend aus CR2' und N;
jeder R2' unabhängig voneinander H oder R2 ist;
jeder R3' unabhängig voneinander H oder R3 ist:
R1 C1-C6-Alkyl, C2-C6-Alkenyl, C2-C6-Alkinyl, C3-C6-Cycloalkyl, C4-C7-Alkylcycloalkyl oder C4-C7-Cycloalkylalkyl ist, jeweils unsubstituiert oder substituiert mit einem oder mehreren
Substituenten unabhängig voneinander ausgewählt aus R4;
R4 Halogen, C1-C6-Alkyl, C1-C6-Alkoxy, C1-C6-Alkylthio, C1-C6-Alkylsulfinyl, C1-C6-Alkyl-sulfonyl, Cyano oder Nitro ist;
jeder R2 unabhängig voneinander Halogen, C1-C6-Alkyl, C1-C6-Halogenalkyl, C1-C6-Alkoxy, C1-C6-Halogenalkoxy, C1-C6-Alkylthio, C1-C6-Halogenalkylthio, C1-C6-Alkylsulfinyl, C1-C6-Halogenalkylsulfinyl, C1-C6-Alkylsulfonyl, C1-C6-Halogenalkylsulfonyl, N-mono- oder N,N-di-C1-C6-Alkylamino, C2-C6-Alkoxycarbonyl, Cyano (-CN) oder Nitro (-NO2) ist;
jeder R3 unabhängig voneinander H, Halogen, C1-C6-Alkyl, C1-C6-Halogenalkyl, C3-C6-Cycloalkyl, C3-C6-Halogencycloalkyl, C1-C6-Alkoxy, C1-C6-Halogenalkoxy, C1-C6-Alkylthio, C1-C6-Halogenalkylthio, C1-C6-Alkyl-sulfinyl, C1-C6-Halogenalkylsulfinyl, C1-C6-Alkylsulfonyl, C1-C6-Halogenalkylsulfonyl, Amino, N-mono- oder N,N-di-C1-C6-Alkylamino, C2-C6-Alkoxycarbonyl, Cyano oder Nitro ist;
Z Halogen, ein Radikal Q oder eine Gruppe -C(W)-NR5R6 ist;
Q ein 5- oder 6-gliedriger heterozyklischer Ring oder ein C6-C10-carbozyklisches Ringsystem oder ein 8-, 9- oder 10-gliedriges fusioniertes hetero-bizyklisches
Ringsystem ist, wobei jeder/jedes von diesen unsubstituiert oder substituiert ist
mit einem oder mehreren Substituenten unabhängig voneinander ausgewählt aus Halogen,
C1-C6-Alkyl, C1-C6-Halogenalkyl, C3-C6-Cycloalkyl, C3-C6-Halogencycloalkyl, C1-C6-Alkoxy, C1-C6-Halogenalkoxy, C1-C6-Alkylthio, C1-C6-Halogenalkylthio, C1-C6-Alkylsulfinyl, C1-C6-Halogenalkyfsulfinyl, C1-C6-Alkylsulfonyl, C1-C6-Halogenalkylsulfonyl, Cyano, Nitro, Amino, N-mono- oder N,N-di-C1-C6-Alkylamino, C1-C6-Alkoxycarbonyl, Sulfonamido, N-mono- oder N,N, di-C1-C6-Alkylsulfonamido, C1-C6-Alkylcarbonylamino, N-mono- oder N,N-di-C1-C6-Alkylaminocarbonyl, C2-C6-Alkanoyl und unsubstituiertem oder Halogen-, C1-C6-Alkyl-, C1-C6-Halogenalkyl-, C1-C6-Alkoxy-, C1-C6-Halogenalkoxy-, Cyano- oder Nitro-substituiertem Phenyl, Benzyl, Benzoyl oder Phenoxy;
W O oder S ist,
R5 und R5' jeweils unabhängig voneinander H, C1-C6-Alkyl, C2-C6-Alkenyl, C2-C6-Alkinyl, C3-C6-Cycloalkyl, C4-C7-Alkylcycloalkyl, C4-C7-Cycloalkylalkyl, C2-C6-Alkylcarbonyl oder C2-C6-Alkoxycarbonyl sind;
R6 H; Q' ist, wobei Q' unabhängig voneinander die Bedeutung von Q aufweist; oder C1-C6-Alkyl, C2-C6-Alkenyl, C2-C6-Alkinyl, C3-C6-Cycloalkyl,
C4-C7-Alkylcycloalkyl oder C4-C7-Cycloalkylalkyl ist, jeweils unsubstituiert oder substituiert mit Halogen, C1-C6-Alkoxy, C1-C6-Alkylthio, C1-C6-Alkylsulfinyl, C1-C6-Alkylsulfonyl, Cyano, Nitro, Amino, N-mono- oder N,N-di-C1-C4-Alkylamino, C3-C6-Cycloalkylamino, C2-C6-Alkoxycarbonyl, C2-C6-Alkanoyl, C2-C6-Alkylcarbonylamino, Aminocarbonyl, N-mono- oder N,N-di-C1-C6-Alkylaminocarbonyl oder einem Radikal Q", wobei Q" unabhängig voneinander die Bedeutung
von Q aufweist; oder
R5 und R6 zusammen mit dem N-Atom an das sie gebunden sind, einen 3-bis 7-gliedrigen Ring bilden,
der gegebenenfalls ein weiteres Heteroatom ausgewählt aus der Gruppe bestehend aus
N, S und O enthält, und welcher Ring weiter unsubstituiert oder substituiert ist mit
C1-C2-Alkyl, C1-C2-Alkyl, C1-C2-Alkoxy, Halogen, Cyano oder Nitro.
3. Verbindung nach Anspruch 1 oder 2, wobei B1, B2 und B3 jeweils CR2 sind.
4. Verbindung nach einem der Ansprüche 1 bis 3, wobei X S(O)m, O oder NR5' ist, einer von X1 und X2 CR3' ist und der andere N oder unabhängig voneinander CR3' ist, wobei R3' jeweils unabhängig voneinander H oder C1-C2-Alkyl ist, R5' H oder C1-C2-Alkyl ist und m eine ganze Zahl von 0 bis 2 ist.
5. Verbindung nach einem der Ansprüche 1 bis 4, wobei R1 Halogen-C1-C3-Alkyl, insbesondere CF3 ist.
6. Verbindung nach Anspruch 1 oder 2 der Formel

wobei R
1, R
2, X, X
1, X
2, Z und n wie in Anspruch 1 definiert sind.
7. Verbindung nach einem der Ansprüche 1 bis 6, wobei Z ein 5- oder 6-gliedriger heterozyklischer
Ring ist, der von 1 bis 4, bevorzugt von 1 bis 3, gleiche oder unterschiedliche Heteroatome
ausgewählt aus der Gruppe bestehend aus N, O und S aufweist, der weiter unsubstituiert
oder substituiert ist mit einem oder mehreren Substituenten ausgewählt aus der Gruppe
bestehend aus C1-C4-Alkyl, C1-C4-Halogenalkyl, C1-C4-Alkoxy, C1-C4-Halogenalkoxy, C1-C4-Alkylthio, C1-C4-Halogenalkylthio, C1-C4-Alkylsulfinyl, C1-C4-Halogenalkylsulfinyl, C1-C4-Alkylsulfonyl, C1-C4-Halogenalkylsulfonyl, Cyano, Nitro, C1-C4-Alkoxycarbonyl, Sulfonamido, N-mono- oder N,N-di-C1-C4-Alkylcarbonylamino, C2-C3-Alkanoyl und unsubstituiertem oder Halogen- oder C1-C4-Alkyl-substituiertem Phenyl, Benzyl, Benzoyl und Phenoxy.
8. Verbindung nach Anspruch 7, wobei Z ein Radikal Q der Formel

ist,
wobei (R)
r 0 bis 3 gleiche oder unterschiedliche Substituenten ausgewählt aus der Gruppe bestehend
aus Halogen, C
1-C
2-Alkyl, C
1-C
2-Halogenalkyl, C
1-C
2-Alkoxy, C
1-C
2-Halogenalkoxy, C
1-C
2-Halogenalkylthio, Cyano, Nitro und C
1-C
4-Alkoxycarbonyl ist.
9. Verbindung nach Anspruch 8, wobei Z das Radikal Q-34 ist, wobei r 0 ist.
10. Verbindung nach einem der Ansprüche 1 bis 6, wobei Z eine Gruppe - C(O)-NR5R6 ist, wobei R5 H, C1-C2-Alkyl, C2-C4-Alkylcarbonyl oder C2-C4-Alkoxycarbonyl ist und R6 C1-C4-Alkyl ist, das substituiert ist mit Halogen, Cyano, Nitro oder einem Radikal Q',
wobei Q' die Bedeutung von Q wie in Anspruch 7 angegeben, aufweist.
11. Verbindung nach Anspruch 10, wobei R5 H ist und R6 C1-C4-Alkyl ist, das substituiert ist mit Halogen oder mit einem Radikal Q-34 oder Q-48
angegeben in Anspruch 7, wobei r 0 ist.
12. Verbindung der Formel (la) nach Anspruch 6, wobei n eine ganze Zahl von 1 bis 3 ist,
R
1 Halogen-substituiertes C
1-C
3-Alkyl ist, jeder R
2 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus Halogen, C
1-C
6-Halogenalkyl, C
1-C
6-Halogenalkoxy und Cyano, X S(O)
m, O oder NR
5' ist, m eine ganze Zahl von 0 bis 2 ist, R
5' H oder C
1-C
2-Alkyl ist, einer von X
1 und X
2 CR
3' ist und der andere N oder unabhängig voneinander CR
3' ist, wobei R
3' jeweils unabhängig voneinander H oder C
1-C
2-Alkyl ist und Z entweder ist
(i) Halogen oder
(ii) ein Radikal Q der Formel

wobei (R)
r 0 bis 3 gleiche oder unterschiedliche Substituenten ausgewählt aus der Gruppe bestehend
aus Halogen, C
1-C
2-Alkyl, C
1-C
2-Halogenalkyl, C
1-C
2-Alkoxy, C
1-C
2-Halogenalkoxy, C
1-C
2-Halogenalkylthio, Cyano, Nitro und C
1-C
4-Alkoxycarbonyl ist, oder
(iii) eine Gruppe -C(O)-NR
5R
6 ist, wobei R
5 H, C
1-C
2-Alkyl, C
2-C
4-Alkylcarbonyl oder C
2-C
4-Alkoxycarbonyl ist und R
6 C
1-C
4-Alkyl ist, das substituiert ist mit Halogen, Cyano, Nitro oder einem Radikal Q-34,
G-48, Q-49 oder Q-50 oben, wobei R und r wie definiert sind.
13. Verbindung der Formel (la) nach Anspruch 6, wobei n eine ganze Zahl von 1 bis 3 ist,
R1 CF3 ist, jeder R2 unabhängig voneinander ausgewählt ist aus der Gruppe bestehend aus Halogen, C1-C6-Halogenalkyl, C1-C6-Halogenalkoxy und Cyano, X S(O)m ist, wobei m eine ganze Zahl von 0 bis 2 ist, insbesondere 0, einer von X1 und X2 CR3' ist und der andere N oder unabhängig voneinander CR3' ist, wobei R3' jeweils unabhängig voneinander H oder C1-C2-Alkyl ist und Z entweder ist (ii) das Radikal Q-34 angegeben in Anspruch 7, wobei
r 0 ist; oder
(iii) eine Gruppe -C(O)-NR5R6, wobei R5 H ist und R6 C1-C4-Alkyl ist, das substituiert ist mit Halogen oder mit einem Radikal Q-34 oder Q-48
angegeben in Anspruch 7, wobei r 0 ist.
14. Verbindung der Formel (I) nach Anspruch 1 oder 6, wobei Z ein Radikal - C(W)-NR5R6 ist, R6 ein Radikal -(alk)-C(W')-NR5"R7 ist, W und W' jeweils unabhängig voneinander O oder S sind, (alk) geradkettiges oder
verzweigtes C1-C4-Alkylen ist und R5, R5" und R7 jeweils wie in Anspruch 1 definiert sind.
15. Verbindung der Formel (la) nach Anspruch 6, wobei Z ein Radikal -C(O)-NR5R6 ist, wobei R5 H ist, R6 ein Radikal -(alk)-C(O)-NR5"R7 ist, (alk) Methylen oder 1,2-Ethylen ist, insbesondere Methylen, R5" H ist und R7 C1-C6-Alkyl ist, das unsubstituiert oder substituiert ist mit Halogen, Cyano oder Pyridyl,
oder C2-C4-Alkinyl oder C3-C4-Cycloalkyl ist.
16. Verbindung der Formel (I) nach Anspruch 1 oder 6, wobei Z ein Radikal Q ist, Q ein
Radikal der Formel

ist
r 1 ist, R ein Radikal -(alk)-C(W)-NR
5"R
7 ist, (alk) geradkettiges oder verzweigtes C
1-C
4-Alkylen ist, W O oder S ist und R
5" und R
7 jeweils wie in Anspruch 1 definiert sind.
17. Verbindung der Formel (la) nach Anspruch 6, wobei Z ein Radikal Q ist, Q ein Radikal
der Formel

ist,
R ein Radikal -(alk)-C(O)-NHR
7 ist, (alk) Methylen oder 1,2-Ethylen ist, insbesondere Methylen und R
7 C
1-C
6-Alkyl ist, das unsubstituiert oder substituiert ist mit Halogen, Cyano oder Pyridyl,
oder C
2-C
4-Alkinyl oder C
3-C
4-Cycloalkyl ist.
18. Verbindung der Formel (I) nach Anspruch 1, die ist
5-[5-(3,5-Dichlor-phenyl)-5-trifluormethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophen-2-carbonsäure
[(2,2,2-trifluor-ethylcarbamoyl)-methyl]-amid; oder
5-[5-(3,5- Dichlor-phenyl)-5-trifluormethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophen-2-carbonsäure
(4-trifluormethyl-thiazol-2-yl)-amid; oder
5-[5-(3,5-Dichlor-phenyl)-5-trifluormethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophen-2-carbonsäure
ethylcarbamoylmethyl-amid; oder
5-[5-(3,5-Dichlor-phenyl)-5-trifluormethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophen-2-carbonsäure
prop-2-inylcarbamoylmethyl-amid; oder
5-[5-(3,5-Dichlor-phenyl)-5-trifluormethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophen-2-carbonsäure
[(cyanomethyl-carbamoyl)-methyl]-amid; oder
5-[5-(3,5-Dichlor-phenyl)-5-trifluormethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophen-2-carbonsäure
[(2,2,2-trifluor-ethylthiocarbamoyl-methyl]-amid; oder
5-[5-(3,5-bis-trifluormethyl-phenyl)-5-trifluormethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophen-2-carbonsäure
[(2,2,2-trifluor-ethylcarbamoyl-methyl]-amid; oder
5-[5-(3,4,5-Trichlor-phenyl)-5-trifluormethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophen-2-carbonsäure
[(2,2,2-trifluor-ethylcarbamoyl-methyl]-amid; oder
5-[5-(3,5-Dichlor-4-fluor-phenyl)-5-trifluormethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophen-2-carbonsäure
[(2,2,2-trifluor-ethylcarbamoyl-methyl]-amid.
19. Verbindung der Formel (I) nach Anspruch 1, die 5-[5-(3,4,5-Trichlorphenyl)-5-trifluormethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophen-2-carbonsäure
[(2,2,2-trifluor-ethylcarbamoyl-methyl]-amid ist.
20. Zusammensetzung zur Kontrolle von Parasiten, umfassend als Wirkstoff mindestens eine
Verbindung der Formel (1) nach einem der Ansprüche 1 bis 19, zusätzlich zu einem Träger
und/oder einem Dispergiermittel.
21. Verwendung einer Verbindung der Formel (1) nach einem der Ansprüche 1 bis 19 bei der
Zubereitung einer pharmazeutischen Zusammensetzung gegen Parasiten in und auf warmblütigen
Tieren.
22. Verwendung nach Anspruch 21, wobei die Parasiten Ektoparasiten ausgewählt aus der
Gruppe bestehend aus Fliegen, Flöhen, Läusen, Milben und Zecken sind.
23. Verwendung nach Anspruch 21, wobei die Parasiten Seeläuse (sea lice) sind.
1. Composé de formule

y compris tous ses stéréoisomères géométriques, N-oxydes, et sels, dans laquelle,
X, est S(O)m, O ou NR
5' et X
1 et X
2 sont chacun indépendamment l'un de l'autre CR
3' ou N,
n est un nombre entier de 0 à 4 ; m est un nombre entier de 0 à 2 ;
B
1, B
2 et B
3 sont chacun indépendamment choisis à partir du groupe composé de CR
2' et N ;
chaque R
2' est indépendamment l'un de l'autre H ou R
2 ;
chaque R
3' est indépendamment l'un de l'autre H ou R
3 ;
R
1 est C
1-C
6-alkyle, C
2-C
6-alcényle, C
2-C
6-alcynyle, C
3-C
6-cycloalkyle, C
4-C
7-alkylcycloalkyle ou C
4-C
7-cycloalkylalkyle, chacun non substitué ou substitué par un ou plusieurs substituants
indépendamment choisis à partir de R
4 ;
R
4 est halogène, C
1-C
6-alkyle, C
1-C
6-alcoxy, C
1-C
6-alkylthio, C
1-C
6-alkylsulfinyle, C
1-C
6-alkylsulfonyle, cyano ou nitro ;
chaque R
2 est indépendamment halogène, C
1-C
6-alkyle, C
1-C
6-haloalkyle, C
1-C
6-alcoxy, C
1-C
6-haloalcoxy, C
1-C
6-alkythio, C
1-C
6-haloalkylthio, C
1-C
6-alkylsulfinyle, C
1-C
6-haloalkylsulfinyle, C
1-C
6-alkylsulfonyle, C
1-C
6-haloalkylsulfonyle, N-mono- ou N,N-di- C
1-C
6-alkylamino, C
1-C
6-alcoxycarbonyle, cyano (CN) ou nitro (-NO
2) ;
chaque R
3 est indépendamment H, halogène, C
1-C
6-alkyle, C
1-C
6-haloalkyle, C
3-C
6-cycloalkyle C
3-C
6-halocycloalkyle, C
1-C
6-alcoxy, C
1-C
6-haloalcoxy, C
1-C
6-alkylthio, C
1-C
6-haloalkyltio, C
1-C
6-alkylsulfinyle, C
1-C
6-haloalkylsulfinyle, C
1-C
6-alkylsulfonyle, C
1-C
6-haloalkylsulfonyle, amino, N-mono- ou N,N-di-C
1-C
6-alkylamino, C
1-C
6-alcoxycarbonyle, cyano, nitro ou phényle, pyridyle ou pyrimidyle non substitués ou
substitués par halogène, C
1-C
6-alkyle, C
1-C
6-haloalkyle, C
1-C
6-alcoxy, C
1-C
6-haloalcoxy, amino, cyano ou nitro ;
Z est halogène, un radical Q ou un groupe -C(W)-NR
5R
6 ;
Q est un cycle hétérocyclique à 5 ou 6 ramifications ou un système cyclique C
6-C
10-carbocyclique ou un système cyclique hétérobicyclique fusionné à 8, 9 ou 10 ramifications,
chacun d'entre eux étant non substitués ou substitués par un ou plusieurs substituants
indépendamment choisis à partir d'halogène, C
1-C
6-alkyle, C
1-C
6-haloalkyle, C
3-C
6-cycloalkyle, C
3-C
6-halocycloalkyle, C
1-C
6-alcoxy, C
1-C
6-haloalcoxy, C
1-C
6-alkylthio, C
1-C
6-haloalkylthio, C
1-C
6-alkylsulfinyle, C
1-C
6-haloalkylsulfinyle, C
1-C
6-alkylsulfonyle, C
1-C
6-haloalkylsulfonyle, cyano, nitro, amino, N-mono- ou N,N-di-C
1-C
4-alkylamino, C
1-C
6-alcoxycarbonyle, sulfonamido, N-mono- ou N,N-di-C
1-C
4-alkylsulfonamido, C
1-C
6-alkylcarbonylamino, N-mono- ou NN-di-C
1-C
6-alkylaminocarbonyle, C
2-C
6-alcanoyle, un groupe -(alk)-C(W')NR
5" R
7, phényle, benzyle, benzoyle, phénoxy, pyridyle, pyridyl-(alk)-, pyrimidyle et pyrimidyl-(alk)-,
dans lequel les groupes phényle, benzoyle, benzoyle, phénoxy, pyridyle et pyrimidyle
sont chacun non substitués ou substitués par halogène, C
1-C
6-alkyle, C
1-C
6-haloalkyle, C
1-C
6-alcoxy, C
1-C
6-haloalcoxy, cyano, nitro ou amino ;
(alk) est C
1-C
6-alcylène à chaîne linéaire ou ramifiée ;
W et W' sont chacun indépendamment l'un de l'autre O ou S,
R
5, R
5' et R
5" sont chacun indépendamment l'un de l'autre H, C
1-C
6-alkyle, C
2-C
6-alcényle, C
2-C
6-alcynyle, C
3-C
6-cycloalkyle, C
4-C
7-alkylcycloalkyle, C
4-C
7-cycloalkylalkyle, C
1-C
6-alkylcarbonyle ou C
1-C
6-alcoxycarbonyle,
R
6 est H ; Q'
caractérisé en ce que Q' possède indépendamment la signification de Q ; ou est C
1-C
6-alkyle, C
2-C
6-alcényle, C
2-C
6-alcynyle, C
3-C
6-cycloalkyle, C
4-C
7-alkylcycloalkyle ou C
4-C
7-cycloalkylalkyle, chacun non substitué ou substitué par halogène, C
1-C
6-alcoxy, C
1-C
6-alkylthio, C
1-C
6-alkylsulfinyle, C
1-C
6-alkylsulfonyle, cyano, nitro, amino, N-mono- ou N,N-di-C
1-C
6-alkylamino, C
3-C
6-cycloalkylamino, C
1-C
6-alcoxycarbonyle; C
2-C
6-alcanoyle, C
1-C
6-alkylcarbonylamino, aminocarbonyle, N-mono- ou N,N-di-C
1-C
6-alkylaminocarbonyle, un groupe -C(W')NR
5"R
7 ou un radical Q", dans lequel Q" possède indépendamment la signification de Q ; ou
R
5 et R
6, de pair avec l'atome d'azote auquel il sont attachés, forment un cycle possédant
de 3 à 7 ramifications qui contient éventuellement un autre hétéroatome choisi à partir
du groupe composé de N, S et O, et dont le cycle est à nouveau non substitué ou substitué
par C
1-C
2-alkyle, C
1-C
2-alkyle, C
1-C
2-alcoxy, halogène, cyano ou nitro ; et
R
7 est C
1-C
6-alkyle, C
2-C
6-alcényle, C
2-C
6-alcynyle, C
3-C
6-cycloalkyle, C
4-C
7-alkylcycloalkyle ou C
4-C
7-cycloalkylalkyle, qui sont chacun non substitué ou substitué par halogène, C
1-C
6-alcoxy, C
1-C
6-alkylthio, C
1-C
6-alkylsulfinyle, C
1-C
6-alkylsulfonyle, cyano, nitro, amino, N-mono- ou N,N-di-C
1-C
6-alkylamino, pyridyle, pyrimidyle ou thiazolyle, ou par pyridyle, pyrimidyle ou thiazolyle
qui sont mono- ou di-substitués par halogène, cyano, C
1-C
2-alkyle ou C
1-C
2-haloalkyle.
2. Composé de formule (I) selon la revendication 1, dans laquelle
X est S(O)m, O ou NR5' et X1 et X2 sont chacun indépendamment l'un de l'autre CR3' ou N,
n est un nombre entier de 0 à 4 ; m est un nombre entier de 0 à 2 ;
B1, B2 et B3 sont chacun indépendamment l'un de l'autre sélectionnés à partir du groupe composé
de CR2' et N ;
chaque R2' est indépendamment de l'autre H ou R2 ;
chaque R3' est indépendamment de l'autre H ou R3;
R1 est C1-C6-alkyle, C2-C6-alcényle, C2-C6-alcynyle, C3-C6-cycloalkyle, C4-C7-alkylcycloalkyle ou C4-C7-cycloalkylalkyle, chacun non substitué ou substitué par un ou plusieurs substituants
indépendamment sélectionnés à partir de R4 ;
R4 est halogène, C1-C6-alkyle, C1-C6-alcoxy, C1-C6-alkylthio, C1-C6-alkylsulfinyle, C1-C6-alkylsulfonyle, cyano ou, nitro ;
chaque R2 est indépendamment halogène, C1-C6-alkyle, C1-C6-haloalkyle, C1-C6-alcoxy, C1-C6-haloalcoxy, C1-C6-alkylthio, C1-C6-haloalkylthio, C1-C6-alkylsulfinyle, C1-C6-haloalkylsulfinyle, C1-C6-alkylsulfonyle, C1-C6-haloalkylsulfonyle, N-mono- ou N,N-di-C1-C6-alkylamino, C2-C6-alcoxycarbonyle, cyano (-CN) ou nitro (-NO2) ;
chaque R3 est indépendamment H, halogène, C1-C6-alkyle, C1-C6-haloalkyle, C3-C6-cycloalkyle, C3-C6-halocycloalkyle, C1-C6-alcoxy, C1-C6-haloalcoxy, C1-C6-alkylthio, C1-C6-haloalkylthio, C1-C6-alkylsulfinyle, C1-C6-haloalkylsulfinyle, C1-C6-alkylsulfonyle, C1-C6-haloalkylsulfonyle, amino, N-mono- ou NN-di-C1-C6-alkylamino, C1-C6-alcoxycarbonyle, cyano ou nitro ;
Z est halogène, un radical Q ou un groupe -C(W)-NR5R6 ;
Q est un cycle hétérocyclique à 5 ou 6 ramifications ou un système cyclique C6-C10-carbocyclique ou un système cyclique hétérobicyclique fusionné possédant 8, 9 ou
10 ramifications, chacun d'entre eux étant non substitués ou substitués par un ou
plusieurs substituants indépendamment choisis à partir d'halogène, C1-C6-alkyle, C1-C6-haloalkyle, C3-C6-cycloalkyle, C3-C6-halocycloalkyle, C1-C6-alcoxy, C1-C6-haloalcoxy, C1-C6-alkylthio, C1-C6-haloalkylthio, C1-C6-alkylsulfinyle, C1-C6-haloalkylsulfinyle, C1-C6-alkylsulfonyle, C1-C6-haloalkylsulfonyle, cyano, nitro, amino, N-mono- ou N,N-di-C1-C6-alkylamino, C1-C6-alcoxycarbonyle, sulfonamido, N-mono- ou N,N, di-C1-C6-alkylsulfonamido, C1-C6-alkylcarbonylamino, N-mono-, ou N,N-di-C1-C6-alkylaminocarbonyle, C2-C6-alcanoyle et phényle, benzyle, benzoyle ou phénoxy non substitués ou substitués par
halogène, C1-C6-alkyle, C1-C6-haloalkyle, C1-C6-alcoxy, C1-C6-haloalcoxy, cyano ou nitro ;
W est O ou S,
R5 et R5' sont chacun indépendamment l'un de l'autre H, C1-C6-alkyle, C2-C6-alcényle, C2-C6-alcynyle, C3-C6-cycloalkyle, C4-C7-alkylcycloalkyle, C4-C7-cycloalkylalkyle, C2-C6-alkylcarbonyle ou C2-C6-alcoxycarbonyle ;
R6 est H ; Q', caractérisé en ce que Q' possède indépendamment la signification de Q ; ou est C1-C6-akyle, C2-C6-alcényle, C2-C6-alcynyle, C3-C6-cycloalkyle, C4-C7-alkylcycloalkyle ou C4-C7-cycloalkylalkyle, chacun non substitué ou substitué par halogène, C1-C6-alcoxy, C1-C6-alkylthio, C1-C6-alkylsulfinyle, C1-C6-alkylsulfonyle, cyano, nitro, amino, N-mono- ou N,N-di-C1-C4-alkylamino, C3-C6-cycloalkylamino, C2-C6-alcoxycarbonyle, C2-C6-alcanoyle, C2-C6-alkylcarbonylamino, aminocarbonyle, N-mono- ou N,N-di-C1-C6-alkylaminocarbonyle ou un radical Q", dans lequel Q" possède indépendamment la signification
de Q ; ou
R5 et R6 de pair avec l'atome d'azote auquel ils sont attachés, forment un cycle possédant
de 3 à 7 ramifications qui contient éventuellement un autre hétéroatome choisi à partir
du groupe composé de N, S et O, et dont le cycle est à nouveau non substitue ou substitué
par C1-C2-alkyle, C1-C2-alkyle, C1-C2-alcoxy, halogène, cyano ou nitro.
3. Composé selon la revendication 1 ou 2, caractérisé en ce que B1, B2 et B3 sont chacun CR2'.
4. Composé selon l'une quelconque des revendications 1 à 3, caractérisé en ce que X est S(O)m, O ou NR5', un des X1 et X2 est CR3' et l'autre est N ou indépendamment CR3', dans lequel R3' est indépendamment H ou C1-C2-alkyle, R5' est H ou C1-C2-alkyle, et m est un nombre entier de 0 à 2.
5. Composé selon l'une quelconque des revendications 1 à 4, caractérisé en ce que R1 est halo-C1-C3-alkyle, tout particulièrement CF3.
6. Composé selon les revendications 1 ou 2 de formule

dans laquelle, R
1, R
2, X, X
1, X
2, Z et n sont tels que définis à la revendication 1.
7. Composé selon l'une quelconque des revendications 1 à 6, caractérisé en ce que Z est un cycle hétérocyclique à 5 ou 6 ramifications possédant de 1 à 4, de préférence
de 1 à 3 hétéroatomes identiques ou différents choisis à partir du groupe composé
de N, O et S, qui est à nouveau non substitué ou substitué par un ou plusieurs substituants
choisis à partir du groupe composé de C1-C4-alkyle, C1-C4-haloalkyle, C1-C4-alcoxy, C1-C4-haloalcoxy, C1-C4-alkylthio, C1-C4-haloalkylthio, C1-C4-alkylsulfinyle, C1-C4-haloalkylsulfinyle, C1-C4-alkylsulfonyle, C1-C4-haloalkylsulfonyle, cyano, nitro, C1-C4-alcoxycarbonyle, sulfonamido, N-mono- ou N,N-di-C1-C4-alkylcarbonylamino, C2-C3-alcanoyle et phényle, benzyle, benzoyle et phénoxy non substitues ou substitués par
halogène ou C1-C4-alkyle,
8. Composé selon la revendication 7,
caractérisé en ce que Z est un radical Q de formule

dans laquelle, (R)
r est de 0 à 3 substituants identiques ou différents choisis à partir du groupe composé
d'halogène, C
1-C
2-alkyle, C
1-C
2-haloalkyle, C
1--C
2-alcoxy, C
1-C
2-haloalcoxy, C
1-C
2-haloalkylthio, cyano, nitro, et C
1-C
4-alcoxycarbonyle.
9. Composé selon la revendication 8, caractérisé en ce que Z est le radical Q-34, dans lequel r est 0.
10. Composé selon l'une quelconque des revendications 1 à 6, caractérisé en ce que Z est un groupe -C(O)-NR5R6, dans lequel R5 est H, C1-C2-alkyle, C2-C4-alkylcarbonyle ou C2-C4-alcoxycarbonyle et R6 est C1-C4-alkyle qui est substitué par halogène, cyano, nitro ou un radical Q' dans lequel
Q' possède la signification de Q telle que donnée à la revendication 7.
11. Composé selon la revendication 10, caractérisé en ce que R5 est H et R6 est C1-C4-alkyle qui est substitué par halogène ou par un radical Q-34 ou Q-48 donné à la revendication
7, dans lequel r est 0.
12. Composé de formule (Ia) selon la revendication 6,
caractérisé en ce que n est un nombre entier de 1 à 3, R
1 est C
1-C
3-alkyle substitué par halogène, chaque R
2 est indépendamment choisi à partir du groupe composé d'halogène, C
1-C
6-haloalkyle, C
1-C
6-haloalcoxy et cyano, X est S(O)
m, O ou NR
5', m est un nombre entier de 0 à 2, R
5' est H ou C
1-C
2-alkyle, un des X
1 et X
2 est CR
3' et l'autre est N ou indépendamment CR
3', dans lequel R
3' est indépendamment H ou C
1-C
2-alkyle, et Z est soit
(i) halogène, ou
(ii) un radical Q de formule




dans laquelle, (R)r est de 0 à 3 substituants identiques ou différents sélectionnés à partir du groupe
composé d'halogène, C1-C2-alkyle, C1-C2-haloalkyle, C1-C2-alcoxy, C1-C2-haloaloxy, C1-C2-haloalkylthio, cyano, nitro et C1-C4-alcoxycarbonyle, ou est
(iii) un groupe --C(O)-NR5R6, dans lequel R5 est H, C1-C2-alkyle, C2-C4-alkylcarbonyle ou C2-C4-alcoxycarbonyle et R6 est C1-C4-alkyle qui est substitué par halogène, cyano, nitro ou un radical Q-34, Q-48, Q-49
ou Q-50 ci-dessus, dans lequel R et r sont tels que définis.
13. Composé de formule (Ia) selon la revendication 6, caractérisé en ce que n est un nombre entier de 1 à 3, R1 est CF3, chaque R2 est indépendamment sélectionné à partir du groupe composé d'halogène, C1-C6-haloalkyle, C1-C6-haloalcoxy et cyano, X est S(O)m, dans lequel m est un nombre entier de 0 à 2, tout particulièrement 0, un des X1 et X2 est CR3' et l'autre est N ou indépendamment CR3', dans lequel R3' est indépendamment H ou C1-C2-alkyle, et Z est soit (ïi) le radical Q-34 donné à la revendication 7, dans lequel
r est 0 ; soit (iii) un groupe -C(O)-NR5R6, dans lequel R5 est H et R6 est C1-C4-alkyle qui est substitué par halogène ou par un radical Q-34 ou Q-48 donné à la revendications
7, dans lequel r est 0.
14. Composé de formule (I) selon la revendication 1 ou 6, caractérisé en ce que Z est un radical -C(W)-NR5R6, dans lequel R6 est un radical -(alk)-C(W')-NR5"R7, W et W' sont chacun indépendamment O ou S, (alk) est C1-C4-alkyléne à chaîne linéaire ou ramifiée et R5, R5" et R7 sont chacun tels que définis à la revendication 1.
15. Composé de formule (Ia) selon la revendication 6, caractérisé en ce que Z est un radical -C(O)-NR5R6, dans lequel R5 est H, R6 est un radical -(alk)-C(O)-NR5"R7, (alk) est méthylène ou 1,2-éthylène, tout particulièrement méthylène, R5" est H, et R7 est C1-C6-alkyle qui est non substitué ou substitué par halogène, cyano ou pyridyle, ou est
C2-C4-alcynyle ou C3-C4-cycloalkyle.
16. Composé de formule (I) selon la revendication 1 ou 6,
caractérisé en ce que Z est un radical Q, Q est un radical de formule

r est 1, R est un radical -(alk)-C(W')-NR
5"R
7, (alk) est C
1-C
4-alkylène à chaîne linéaire ou ramifiée, W' est O ou S, et R
5" et R
7 sont chacun tels que définis à la revendication 1.
17. Composé de formule (Ia) selon la revendication 6,
caractérisé en ce que Z est un radical Q, Q est un radical de formule

R est un radical -(alk)-C(O)-NHR
7, (alk) est méthylène ou 1,2-éthylène, tout particulièrement méthylène, et K
7 est C
1-C
6-alkyle, qui est non substitué ou substitué par halogène, cyano ou pyridyle, ou est
C
2-C
4-alcynyle ou C
3-C
4-cycloalkyle.
18. Composé de formule (I) selon la revendication 1, qui est
[(2,2,2-trifluoro-éthylcarbamoyl)-méthyl]-amide d'acide 5-[5-(3,5-dichlorophényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-3-méthyl-thiophène-2-carboxylique;
ou
(4-trifluorométhylthiazol-2-yl)-amide d'acide 5-[5-(3,5-dichloro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-3-méthyl-thiophène-2-carboxylique
; ou
éthylcarbamoylméthyl-amide d'acide 5-[5-(3,5-dichloro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-3-méthyl-thiophène-2-carboxylique
; ou
prop-2-ynylcarbamoylméthyl-amide d'acide 5-[5-(3,5-dichloro-phenyl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-3-méthyl-thiophène-2-carboxylique
; ou
[(cyanométhyl-carbamboyl)-méthyl]-amide d'acide 5-[5-(3,5-dichloro-phényl)-5--trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-3-méthyl-thiophène-2-carboxylique;
ou
[(2,2,2-trifluoro-éthylthiocarbamoyl)-méthyl]-amide d'acide 5-[5-(3,5-dichhlorophényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-3-méthyl-thiophène-2-carboxylique
ou
[(2,2,2-trifluoro-éthylcarbamoyl)-méthyl]-amide d'acide 5-[5-(3,5-bis-trifluorométhyl-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-3-méthylthiophène-2-carboxylique
; ou
[(2,2,2-trifluoro-éthylcarbamoyl)-méthyl]-amide d'acide 5-[5-(3,4,5-trichlorophényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-3-méthyl-thiophène-2-carboxylique
; ou
[(2,2,2-trifluoro-éthylcarbamoyl)-méthyl]-amide d'acide 5-[5-(3,5-dichloro-4-fluoro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-méthyl-thiophène-2-carboxylique.
19. Composé de formule (I) selon la revendication 1, qui est le [(2,2,2-trifluoroéthylcarbamoyl)méthyl]-amide
d'acide 5-[5-(3,4,5-trichloro-phènyl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-3-méthyl-thiophène-2-carboxylique.
20. Composition destinée au contrôle des parasites, comprenant, en tant que principe actif,
au moins un composé de formule (1) selon l'une quelconque des revendications 1 à 19,
en plus d'un véhicule et/ou d'un agent de dispersion.
21. Utilisation d'un composé de formule (I) selon l'une quelconque des revendication 1
à 19 dans la préparation d'une composition pharmaceutique destinée à agir à l'encontre
des parasites présents dans et sur les animaux à sang chaud.
22. Utilisation selon la revendication 21, caractérisée en ce que les parasites sont des ectoparasites choisis à partir du groupe composé des mouches,
des puces, des poux, des mites et des tiques.
23. Utilisation selon la revendication 21, caractérisée en ce que les parasites sont des poux.